,PageNo,Text
0,page_1,"['MC1752', '1', 'Mayo Clinic Cancer Center', 'Phase II study evaluating combination chemotherapy + Radiotherapy (RT) with avelumab in', 'muscle invasive bladder cancer.', 'Sponsor/Principal Investigator: Parminder Singh, MD', 'Mayo Clinic', '5777 E. Mayo Blvd', 'Phoenix, AZ 85054', '480-301-8000 (Phone)', '480-301-4675 (FAX)', 'Co-Principal Investigators:', 'Co-Investigators:', 'Statistician:', 'FDA IND #: 139335', 'Trial Supported by:', 'Funding: EMD Serono', 'Drug Availability:', 'Commercial Agents: 5 - Flourouracil, mitomycin, cisplatin', 'Drug Company Supplied: avelumab', 'NStudy contributor(s) not responsible for patient care', 'Protocol Version Date: 21JUN2018']"
1,page_2,"['MC1752', '2', 'Document History', '(Effective Date)', 'Activation', '19Sep2018', 'Protocol Resources', 'Questions:', 'Contact Name:', 'Patient eligibility*, test schedule,', 'Data Manager', 'treatment delays/interruptions/adjustments,', 'Phone:', 'dose modifications, adverse events,', 'forms completion and submission', 'Forms completion and submission', '(Arizona Coordinator)', 'Phone:', '(Arizona Data Coordinator)', 'Phone:', 'Protocol document, consent form,', 'Sr. Research Protocol Specialist', 'regulatory issues', 'Serious Adverse Event Reporting', 'SAE Coordinator', '*No waivers of eligibility allowed', 'Protocol Version Date: 21JUN2018']"
2,page_3,"['MC1752', '3', 'Table of Contents', 'Phase II study evaluating combination chemotherapy + Radiotherapy (RT) with avelumab in', 'muscle invasive bladder cancer.', '1', 'Protocol Resources', '2', 'Table of Contents', '3', '1.0', 'Background', '5', '2.0', 'Goals', '12', '3.0', 'Registration Patient Eligibility', '13', '4.0', 'Test Schedule', '16', '5.0', 'Grouping Factor:', '19', '6.0', 'Registration Procedures', '19', '7.0', 'Protocol Treatment', '22', '8.0', 'Dosage Modification Based on Adverse Events', '27', '9.0', 'Ancillary Treatment/Supportive Care', '37', '10.0', 'Adverse Event (AE) Monitoring and Reporting', '43', '11.0', 'Treatment Evaluation', '52', '12.0', 'Descriptive Factors:', '53', '13.0', 'Treatment/Follow-up Decision at Evaluation of Patient', '53', '14.0', 'Body Fluid Biospecimens', '55', '15.0', 'Drug Information', '55', '16.0', 'Statistical Considerations and Methodology', '64', '17.0', 'Pathology Considerations/Tissue Biospecimens', '70', '18.0', 'Records and Data Collection Procedures', '72', '19.0', 'Budget Considerations', '72', '20.0', 'References', '73', 'Appendix I', 'ECOG Performance Status', '75', 'Appendix II', 'EORTC QLQ-C30', '76', 'Appendix III', 'EORTC QLQ-BLM30', '78', 'Appendix IV', 'Patient Information Sheet', '81', 'Protocol Version Date: 21JUN2018']"
3,page_4,"['MC1752', '4', 'Schema', 'For the run-in portion only, prior to discussing protocol entry with the patient, call the MCCC', 'Registration Office', '(', ') to insure that a place on the protocol is open to the patient.', 'Registration', 'Concurrent chemo RT + (Avelumab', 'x10 cycles)', 'End of Treatment (30 days after last', 'avelumab dose)', 'Events at any time:', 'Disease Progression', 'Intolerable adverse effects', 'Pregnancy', 'Patient refusal', 'Clinical Follow-up (CFU) 6 month,', '9 month, 12 month after registration', 'Cycle = 14 days', 'NOTE: All cycles will be based on avelumab given once every 14 days.', ""Chemo therapy may be given as clinically indicated and any delays are per healthcare provider's"", 'discretion. Radiation therapy to be given as clinically indicated per section 7.2. Options for concurrent', 'chemotherapy (Providers choice) listed below. They do not affect the cycle length. (See Section 7.1)', 'Generic name: avelumab', 'Generic name: 5-fluorouracil', 'Brand name(s): Bavencio', 'Brand name(s): Adrucil', 'Mayo Abbreviation: AVELUMAB', 'Mayo Abbreviation: 5FU', 'Availability: Drug company providing to Mayo', 'Availability: Commercial', 'Clinic Pharmacy', 'Generic name: mitomycin', 'Generic name: cisplatin', 'Brand name(s): Mutamycin', 'Brand name(s): Platinol', 'Mayo Abbreviation: MITOC', 'Mayo Abbreviation: CDDP', 'Availability: Commercial', 'Availability: Commercial', 'Protocol Version Date: 21JUN2018']"
4,page_5,"['MC1752', '5', '1.0', 'Background', '1.1', 'Defining clinical unmet need', 'In the US alone over 75,000 new patients are diagnosed every year with bladder cancer', 'and the median age is 73 years. Treatment patterns in the community consistently', 'demonstrate that despite potential lethal outcomes, many patients with bladder cancer do', 'not receive appropriate aggressive and potentially curative therapy. Analysis of over', '28,000 patients with T2-T4a bladder cancer in National cancer database showed that only', '52% patients received aggressive therapy for their bladder cancer and over 25% patients', 'received observation only. [1] As our population is aging, the predominant proportion of', 'the newly diagnosed patients are elderly and they are even at higher risk of not receiving', 'appropriate care. A recent NCDB analysis evaluated over 9000 patients diagnosed with', 'bladder cancer with age greater than 80. [2] They observed that only 4.2 percent of the', 'patients received standard of care chemotherapy followed by radical cystectomy, while', '44% underwent TURBT alone. A study looking at data from the SEER database', 'demonstrated that only 21% of patients received radical cystectomy for stage II or higher', 'bladder cancer. At the same time radical cystectomy can potentially be a life changing', 'event for many patients. Even in experienced specialized centers, radical cystectomy', 'entails a high risk of morbidity(up to 60%) and mortality of up to (2.5%)[3] A number of', 'patients may not be fit for or refuse radical cystectomy These data clearly indicate the', 'need to improve access to definitive therapy and to test strategies to improve the', 'outcomes with CRT.', 'Combined analysis of RTOG/NRG patients enrolled on concurrent CRT trials has shown', 'a complete response rate of 69% with five-year overall survival of 57% and disease-', 'specific survival of 71%.[4, 5] In a propensity-matched retrospective analysis the group', 'from Princess Margaret Hospital in Toronto reported no differences in 5-year disease-', 'specific survival between trimodality therapy and radical cystectomy (RC) (76.6% VS.', '73.2%, p=0.49).[6] In a recent 2017 guideline paper from collaborative panel of experts', 'from American Urological Association, American Society of Clinical Oncology,', 'American Society of Radiation Oncology and Society of Urologic Oncology', 'recommended that bladder preservation therapy is the preferred treatment for patients', 'desiring bladder preservation and understand the unique risks associated with this', 'approach and/or those who are medically unfit for surgery.[19]', '1.2', 'Development of concurrent CRT in bladder cancer', 'Cisplatin as single agent or in combination with 5-FU had traditionally been the drug of', 'choice for radio- sensitization. Earlier trials investigated the role of neoadjuvant', 'chemotherapy prior to radiation alone and demonstrated 6% absolute survival advantage', 'at 10 years. Subsequent trials investigated the role of neoadjuvant chemotherapy', 'followed by CRT. In one of these trials, RTOG 89-03, patients were randomized to', 'concurrent CRT with or without neoadjuvant chemotherapy. The trial was prematurely', 'closed when an increased incidence of neutropenic complications was observed. The', 'analysis of enrolled patients showed no significant benefit of neoadjuvant', 'chemotherapy.[9 In the large phase III trial BC2001, where neoadjuvant chemotherapy', 'was allowed but not mandated, one third of patients received neoadjuvant chemotherapy.', 'The primary endpoint of loco-regional disease control was not different in the group', 'receiving neoadjuvant chemotherapy as compared to the one without chemotherapy.', 'BC2001 also demonstrated that an alternative chemotherapy regimen, 5- fluorouracil and', 'mitomycin, can be used effectively, including in patients with poor renal function who', 'Protocol Version Date: 21JUN2018']"
5,page_6,"['MC1752', '6', 'are cisplatin-ineligible. The overall loco-regional disease free survival at 2 years were', '67% in the CRT group and 54% in the radiotherapy group( HR=0.68 p=0.03) This trial', 'also investigated two different radiotherapy schedules and doses in a 2-by-2', 'randomizations, 55 Gy in 20 fractions VS 64 in 32 fractions and whole -bladder', 'VS', 'modified volume radiotherapy. There was no observed difference in outcomes between', 'the schedules. [10] The recent updated results of BC2001 continue to show no difference', 'in os or metastases free survival between the groups receiving or not receiving', 'neoadjuvant chemotherapy.[11] A small phase II trial evaluated weekly gemcitabine and', '52.5 Gy radiation in 20 fractions. Complete response was observed in 88% of patients at', 'the time of first post treatment cystoscopy. One patient underwent cystectomy for toxicity', 'and 1 patient had bowel toxicity requiring bowel resection. Overall durable local control', 'and acceptable toxicity were observed in the treated patients.[12 This led to a larger', 'phase II trial by RTOG/NRG (0712) evaluating gemcitabine versus 5 -FU and cisplatin', 'combined with radiotherapy. The data was presented at ASTRO 2017 showing safety and', 'efficacy of gemcitabine in combination with radiation in bladder cancer. A number of', 'Canadian groups (Princess Margaret Hospital - personal communication) are already', 'using gemcitabine as standard chemotherapy with radiation.', 'Despite improvements in chemotherapy options and radiation therapy technology, the', 'outcomes with patients with bladder cancer remain poor with less than 50% surviving 5', 'years. Bladder preservation strategies need to evolve in order to improve long-term', 'outcomes for the growing need of patients who are ineligible for full dose cisplatin based', 'neoadjuvant chemotherapy and/or are either refusing or ineligible for radical cystectomy.', 'Table 1 summarize the results from various bladder preservation trials', 'Study', 'Dose', 'Chemotherapy', 'N', 'CR', '5-yr', '5-yr', '5-yr os', 'Intact', 'LRFS', '(doses in mg/m2)', 'Bladder', '85-', '64 Gy', 'C100', '47', '66', '42%', '45%', '52%', '12[13]', '%', '88-', '39.6 Gy', 'NAC M30 + C70 + V3', '90', '75', '44%', '45%', '51%', '02[14]', 'C70', '%', '(4yr)', '(4yr)', '89-', '64.8 Gy', 'NAC M30 + C70 + V3', '12', '59', '38%', '60%', '49%', '03[9]', 'C100', '3', '%', '95-', '44 Gy (BID', 'C15 + 5FU400 (3d x', '34', '67', '66%', '65%', '83%', '06[15]', 'fxns)', 'wkly)', '%', '(3yr)', '(3yr)', '(3yr)', '97-', '64.8 Gy (BID', 'C20 (2d x wkly)', '47', '74', '48%', '73%', '61%', '06[16]', 'fxns)', '%', '(3yr)', '(3yr)', '(3yr)', '99-', '64.3 Gy (BID', 'C20 + P50 (2d x wkly)', '81', '87', '69%', 'NR', '79%', '06[17]', 'fxns)', 'GC x 4 (Adj)', '%', '(2yr)', '(2yr)', '02-', '64.3 Gy (BID', 'C15 + 5FU400 / C15 +', '93', 'NR', 'NR', 'NR', '73%', '33[18]', 'fxns)', 'P50 (3d x wkly)', 'GCP', '(2yr)', '(Adj)', 'TROG', '64 Gy', 'C35 (1d x wkly)', '11', '70', '61%', '45%', '50%', '9701/99', '6', '%', '(DSS)', '06[19]', 'Protocol Version Date: 21JUN2018']"
6,page_7,"['MC1752', '7', 'BC2001 55-64 Gy', '5FU500 + MMC12 (5d', '36', 'NR', '89%', '82%', '48%', '[10]', 'CI)', '0', '(2yr)', '(2yr)', 'Table 1: CRT Clinical Trial Results [9, 10, 13-19]', '(N = number of patients, CR = complete response rate, yr = year, LRFS = local relapse free survival, os', '= overall survival, Gy = gray, C = cisplatin, NAC = neoadjuvant chemotherapy, M = methotrexate, V =', 'vinblastine, BID = twice daily, fxns = fractions, 5FU = 5-fluorouracil, d = days, wkly = weekly, P =', 'paclitaxel, G = gemcitabine, Adj = adjuvant chemotherapy, NR = not reported, TROG = Tazmanian', 'radiation oncology group, DSS = disease specific survival, MMC = mitomycin C, CI = continuous', 'infusion)', '1.3', 'Rationale for combining immune checkpoint inhibition and concurrent chemo', 'radiation', 'In recent years checkpoint inhibitor therapy (CPI) has been approved for multiple cancer', 'types including bladder cancer. These drugs have shown significant activity in patients', 'who are cisplatin ineligible and those that have progressed following treatment with first', 'line platinum based chemotherapy[11, 20-23]. These drugs are known for their', 'durability of response and excellent tolerability but limited overall response rate.', 'Both chemotherapy and radiotherapy have pleiotropic effects on the immune system that', 'can potentially trigger an antitumor response. It has been shown in pre-clinical and', 'clinical settings that checkpoint inhibition in combination with either modality of therapy', 'can augment and sustain this antitumor activity. For example, Apetoh et al. demonstrated', 'the emission of a danger signal known as high mobility box binding protein-1 (HMGB1)', 'from dying tumor cells in response to either chemotherapy or radiotherapy.[ [24] Tumor', 'HMGB1 expression in combination with toll-like receptor-4 (TLR4) expression on', 'dendritic cells was shown to be prerequisites for effective tumor antigen presentation.', 'Another example is demonstrated with anthracyclines, which are used in the treatment', 'of', 'both NMIBC and MIBC. Anthracyclines induce rapid production of type I interferons,', 'which in turn induce chemokine ligand 10 (CXCL10) release which is intricately', 'involved in tumor cell death. [25] Wu et al. demonstrated in cell lines that radiation can', 'induce PD-L1 expression in tumor cells and addition of a PD-L1 inhibitor to radiation', 'decreased cell proliferation and augmented cell death. [26] The same group investigated', 'PD-L1 expression in pre-treatment biopsies in patients who had received concurrent', 'CRT for bladder cancer. They observed that high PD-L1 expression was significantly', 'associated with lower complete response rates after CRT. Recently published studies in', 'non-small cell lung cancer demonstrated superior efficacy and safety of combining', 'checkpoint inhibitors and chemotherapy vs. chemotherapy alone leading to a change in', 'treatment paradigm[27 In a retrospective series of lung cancer patients who had received', 'prior radiation, either- concurrent with or following checkpoint inhibition therapy, the', 'authors observed a modest increased risk of severe side effects especially in the group', 'receiving radiation after immunotherapy.[28 Multiple groups have published their', 'experience in melanoma and lung cancer with combining radiation and checkpoint', 'inhibitors reporting abscopal effects raising the possibility of not only improving local', 'control but also of reducing systemic recurrences. [29, 30].', 'Data from these studies is hypothesis generating and suggest that a combinatorial strategy', 'of CRT and checkpoint inhibition could improve outcome in localized muscle invasive', 'bladder cancer. There is potential for an increase in local GI, GU and systemic immune-', 'related side effects that would need to be balanced with the potential benefit of', 'Protocol Version Date: 21JUN2018']"
7,page_8,"['MC1752', '8', 'combination therapy. There is clearly an unmet need to optimize the integration of these', 'therapies in order to lower the impact of potential antagonistic interactions and also', 'assess additive toxicity.', 'In this study we are testing the efficacy of avelumab in combination with concurrent', 'CRT. Avelumab, (MSB0010718C) is an investigational fully human anti-PD-L1 IgG1', 'antibody that inhibits PD-1/PD-L1 interactions while leaving the PD-1/PD-L2 pathway', 'intact. This enhances immune activation against tumor cells. Unlike other anti-PD-', 'L1/PD-1 antibodies that are approved or in advanced clinical development, avelumab', 'induces lysis of tumor cells via antibody-dependent cell-mediated cytotoxicity in vitro,', 'suggesting an additional mechanism of action. Importantly, avelumab has not shown', 'antibody-dependent cell-mediated cytotoxicity against immune cell subsets in humans.', 'In a large phase Ib study evaluating range of tumor types, avelumab showed activity in a', '44 patient cohort of patients with metastatic urothelial carcinoma refractory to', 'chemotherapy. Subsequent study including two hundred and forty two patients with', 'locally advanced or metastatic urothelial carcinoma with disease progression on or after', 'platinum containing chemotherapy. The confirmed overall response rate was 13 % at 13', 'week follow up. Toxicities were consistent with this class of drugs with 5.5% of patients', 'having grade 3-4 treatment related toxicity. Based on this study it received approval for', 'use in patients with urothelial carcinoma who have progressed on platinum containing', 'chemotherapy. The proposed study will be a phase II single arm trial evaluating', 'combination of chemoradiation with avelumab in patients with T2-T4a NOMO bladder', 'cancer. The trial has built in safety run in of 6 patients and accrual will be stopped to', 'evaluate toxicity after 6 patients are enrolled.', '1.4', 'Safety data from combination of immunotherapy and radiation or chemotherapy.', 'Safety of immunecheckpoint inhibitors in combination with chemoradiation for bladder is', 'not established. However there is data from other tumor types which shed light on', 'activity and potential adverse events. Pembrolizumab was recently approved in', 'combination with chemotherapy in lung cancer. This approval was based on a phase III', 'trial as mentioned above. The most common immune-mediated adverse events of any', 'grade in avelumab plus chemotherapy groups were hypothyroidism(159', 'hyperthyroidism(8%) and pneumonitis (5%).Overall no significant increase in toxicity as', 'compared to chemotherapy alone arm. Interestingly, in a previous trial evaluating', 'avelumab alone VS physician choice chemotherapy in lung cancer, hypothyroidism was', 'observed in (9%) of patients, hyperthyroidism (7.8%) and pneumonitis (5.8%). Another', 'phase III study evaluating durvalumab consolidation after definitive chemoradiotherapy', 'in lung cancer observed 3.4% grade 3-4 immune related side effects VS 2.6% in the', 'placebo arm. [31] This lead to recent apporval of durvalumab in lung cancer for', 'maintainence therapy after concurrent chemoradiation.', 'There is ongoing phase I/II trial of gemcitabine with radiation and pembrolizumab for', 'muscle invasive bladder cancer at New York University hospital. Among 6 patients', 'enrolled by December 2017 one patient had dose limiting toxicity of diarrhea which', 'responded to steroids. (personal communication with Arjun Balar, MD) another similar', 'trial opened through Australian and New Zealand Urogenital and Prostate cancer trials', 'group is evaluating pembrolizumab with cisplatin and radiation for localized muscle', 'invasive bladder cancer. The trial has enrolled 4 patients who all have finished their', 'concurrent chemoradiation and are currently on adjuvant avelumab by December 2017(', 'personal communication Andrew Weickhardt, MD ) . None of the patients had any grade', '3-4 toxicity which would require treatment delays.', 'Protocol Version Date: 21JUN2018']"
8,page_9,"['MC1752', '9', 'No published safety data exist with avelumab or any other checkpoint inhibitor therapies', 'in patients receiving definitive pelvic radiation doses of up to 64.8 Gy as is standard in', 'MIBC. IMpower132 is evaluating atezolizumab in combination with cisplatin and', 'pemetrexed in lung cancer and safety analysis is expected in first quarter of 2018.', 'Atezolizumab is also being investigated in a phase II trial in combination with concurrent', 'chemotherapy and radiation in lung cancer at MD Anderson cancer center. In personal', 'communication with the Stephen Li(PI) 25 patients have been enrolled on to the study.', 'Fifteen patients have finished their protocol assigned treatment with only one patient', 'having immune related pneumonitis. This patient was taken off atezolizumab and', 'responded to steroids and recovered completely. No excess toxicity was observed and all', 'patients completed the protocol assigned concurrent chemoradiation therapy.', 'While the safety data of avelumab is impressive thus far, MIBC patients represent a', 'patient population in which the goal of therapy in not only cure of bladder cancer but', 'also reduce morbidity associated with the treatment. This proposal will give us insights', 'into the safety of combining immune check point inhibitor with concurrent', 'chemoradiation. Therefore this trial has been designed to evaluate both early signals of', 'safety and maintain close monitoring throughout the trial for any excessive toxicity. The', 'translational work associated with the clinical trial will help prepare for preliminary data', 'for similar proposal that we will prepare for the phase III clinical trial which PI is', 'preparing for NCI.', '1.5', 'Correlative Research', 'It is becoming increasingly recognized that cancers can thrive upon evading the immune', 'system. Malignancies such as urothelial carcinoma, melanoma and renal cell carcinoma', 'are known to exploit the programmed death 1 (PD-1) pathway in order to evade the', 'immune system through adaptive immune resistance. [1-3] Monoclonal antibodies', 'targeting PD-1 have recently been introduced, and have been shown to improve survival', 'when used in patients with advanced bladder cancer who have previously failed prior', 'cisplatin based chemotherapy or are ineligible for chemotherapy.[1, 4-6]', 'The success of PD-1 blockade therapy in treatment of solid cancers is dependent on the', 'presence of pre-existing tumor-reactive CD8+ T lymphocytes[3, 7]. Sharma et al had', 'shown previously that patients with advanced urothelial carcinoma have higher numbers', 'of CD8+ TILs within the tumor. They also observed positive correlation of advanced', 'stage and better disease free survival and overall survival with higher number of CD+8', 'cells. 7]We and others have established that PD-1 and CD11a can be used to identify', 'tumor-reactive CD8+ cytotoxic T lymphocytes in the peripheral blood or in tumor tissues', '[8-10]. We observed that patients with advanced cancers have high levels of', 'CD11ahighPD-1+ CD8+ T cells in peripheral blood [8].', 'Bim (BCL-2-interacting mediator of cell death) is a downstream pro-apoptotic signaling', 'molecule of PD-1 in antigen-primed CD8+ T-cells [11]. Interaction of PD-L1 (the ligand', 'expressed on tumor cells) with PD-1 (on the cell surface of T-cells), leads to the', 'upregulation of Bim in tumor-reactive (PD-1+ CD11a high) CD8+ T-cells [2]. Given that', 'Bim is a pro-apoptotic mediator, this upregulation essentially leads to the removal of', 'tumor-reactive effector CD8+ T-cells from the memory pool, which leads to tumor', 'resistance to the immune system.[2 Interestingly, in patients with metastatic melanoma', 'who did not receive anti-PD-1 therapy, high levels of Bim in circulating PD-1+ CD11a', 'high CD8+ T-cells predicted poor survival, while it was predictive of clinical benefit with', 'treatment using anti-PD-1 therapy. Furthermore, the frequency of Bim+ PD-1+CD11a+', 'CD8+ T-cells decreased in responders to anti-PD-1 therapy, but not in non-responders.', 'Protocol Version Date: 21JUN2018']"
9,page_10,"['MC1752', '10', '[2] All this data and common theme in response to immune therapy among various solid', 'tumors begs investigation in bladder cancer which is a solid tumor in which', 'immunotherapy appears to be very effective in select group of patients. It remains to be', 'evaluated whether high levels of Bim in circulating PD-1+ CD11a high CD8+ T-cells are', ""associated with more aggressive disease in bladder cancer and it's eventual impact on"", 'outcomes with concurrent chemoradiation and immunotherapy.', 'On the other hand, we recently identified that CX3CR1 defined a PD-1 therapy-', 'responsive CD8+ T cells with effector memory phenotype and function. In responders to', 'PD-1 therapy or combined (chemotherapy), CX3CR1 identified an increased CD8 T cell', 'population with effector function and endure cytotoxic chemotherapy drugs. Thus,', 'measurement of CX3CR1+ among CD11a high CD8 T cells will give us a full coverage', 'of therapy-responsive T cell population for understanding the potential cellular', 'mechanism underlying clinical outcomes in patients following immunotherapy or', 'combined therapy.', 'Myeloid-derived suppressor cells (MDSCs) which comprise of heterogenous population', 'of cells consisting of myeloid progenitor cells and immature myeloid cells have been', 'associated with cancer progression and tumor - induced immune dysfunction in variety', 'of solid and hematologic malignancies including bladder cancer. MDSCs cells observed', 'in bladder cancer expressed CD11b+CD33lowHLA-DR-CD3- -', 'CD11b+CD33lowHLA-DR-CD3- cells were significantly higher peripheral blood in', 'bladder cancer patients as compared to healthy donors and correlated with advanced stage', '(Ta/T1 VS T2-4). In a Mayo study of prostate cancer patients undergoing salvage', 'lymphadenectomy, we evaluated compared CD14+ monocytic and CD14- granulocytic', 'MDSCs, and found that the latter exhibited immunosuppressive activity with high', 'expression of PD-L1 (Sharma, Dong and Karnes; unpublished). Given the presence of a', 'systemic immune dysfunction in BC, this warrants further study in patients with BC.', 'Specifically, it is unclear whether higher MDSC levels (and the relative proportions of', 'the granulocytic and monocytic subtypes) in the peripheral blood are associated with', 'adverse clinical outcomes after concurrent chemoradiation and immunotherapy.', 'Clinical response to chemoradiotherapy (CRT) combined with immunotherapy (CIRT)', 'may be predicted by both genomic and immune-based markers (1,2). It is anticipated', 'that the addition of immunotherapy to CRT will improve the immune response to', 'bladder-directed CRT by global alteration of T-cell function. Augmented response to', 'combination CRT and immunotherapy (CIRT) may occur by several mechanisms', 'including 1) increased numbers of neoantigens, 2) induction of tumor antigen-specific', 'immune response after CRT resulting in cross presentation of released tumor antigens by', 'dendritic cells in draining lymph nodes and 3) reversal of T-cell exhaustion by immune', 'checkpoint inhibitors leading to improved clinical response compared to CRT alone (3).', 'A large single arm phase II trial (IMvigor210) with two large independent parallel', 'bladder cancer cohorts (310 and 119 patients) showed that higher TMB was very strongly', 'associated with higher response rate and longer overall survival with atezolizumab (P <', '0.0001; Rosenberg et al. Lancet 2016; Balar et al. Lancet 2016). In the confirmatory large', 'IMvigor 211 phase III clinical trial, 931 bladder cancer patients were randomized to', 'atezolizumab or chemotherapy. In patients with higher TMB (N=274), overall survival', 'was longer with atezolizumab vs. chemotherapy (median 11.3 months [95%CI 8.7-13.2]', 'vs 8.3 months [7.2-10.4]; HR 0.68, 95%CI 0.51-0.90), while in patients with low TMB', '(N=270), survival was similar in treatment arms (median 8.3 months [6.4-9.8] vs 8.1', 'months [6.2-10.4]; 1.00, 0.75-1.32 (Powles T et al. Lancet 2017). Moreover, higher', 'TMB correlated with better response to immunotherapy in a variety of tumor types', 'Protocol Version Date: 21JUN2018']"
10,page_11,"['MC1752', '11', '(Goodman AM et al. Mol Cancer Ther. 017;16(11):2598-2608). In addition, recent data', 'support that the large proportion of mutant neoantigens in mismatch repair-deficient', 'tumors, as well as those with DNA damage response gene mutations, render them', 'sensitive to immune checkpoint blockade in several solid tumors, including bladder', 'cancer (Le DT et al. Science. 2017;357(6349):409-13; Teo et al. 2017 ASCO Meeting;', 'Iyer et al. 2017 ASCO Meeting). Therefore, a critical goal is to assess predictors of', 'response to local and systemic immune activity.', 'The predicted somatic neoantigenic load is a product of the somatic TMB. Somatic', 'mutations result in the formation of altered peptides recognized as ""non-self"" by the', 'immune system These 9- to 11-amino acid peptides termed nonamers are subsequently', 'presented in the major histocompatibility complex (MHC)- class I context and recognized', 'by cytotoxic T cells This suggests that a high mutational burden would evoke a more', 'robust antitumor immune response that could be reinvigorated by ICIs. Several studies', 'show the correlation between mutational load and response to ICIs in advanced UC13', 'and other cancers In primary muscle-invasive bladder UC, patients with fewer', 'neoantigens have shorter RFS compared to those with a high neoantigenic load.', 'The predicted neoantigenic burden was previously reported as a favorable prognostic', 'indicator of increased patient survival in six major cancer types (colorectal, ovary, breast,', 'brain, kidney, and lung). Inferring the MHC haplotypes from the sequence of germline', 'DNA and combining this information with somatic mutational data can help predict', ""mutant nonamers that can bind to patients' specific MHC complexes."", 'PD-L1 expression was previously thought of a possible predictor of response to IO', 'therapy. Multiple studies published in bladder cancer failed to make that correlation.', 'Keynote 045, Phase III randomized trial evaluating pembrolizumab vs chemotherapy in', 'secondline setting in patients who had previous platin based therapy had co primary end', 'points among all patients and among patients who had a tumor PD-L1 ligand combined', 'positive score of 10% or more. The results showed no significant difference in duration', 'of os and PFS among total population and the group who had PD-L1 CPS of 10% or', 'more. (p=0.24) Similar study ImVigor 211 evaluating atezolimab vs chemotherapy in', 'second line setting in patients with advanced urothelial carcinoma showed no difference', 'in outcomes in overall survival among two treatment arms clearly indicating that may be', 'PD-L1 is not a good predictive but a prognostic marker. In our study we will evaluate', 'PD-L1 expression on the immune and tumor cells using panel of antibodies available at', 'Mayo and assess its correlation to response with chemoradiation.', 'Hypothesis:', '1. Concurrent chemo-immuno- radiotherapy is safe and efficacious for patients with', 'bladder cancer opting for bladder salvage.', 'Protocol Version Date: 21JUN2018']"
11,page_12,"['MC1752', '12', '2.0', 'Goals', '2.1', 'Primary Goal', '2.11', 'To evaluate the complete response rate of concurrent chemotherapy radiation', 'treatment combined with avelumab for patients with muscle invasive bladder', 'cancer.', '2.2', 'Secondary Goals', '2.21', 'To evaluate the safety and toxicity (adverse event profile) of concurrent', 'chemotherapy radiation treatment combined with avelumab.', '2.22', 'To evaluate quality of life (QoL) at 1 year of concurrent chemotherapy radiation', 'treatment combined with avelumab.', '2.23', 'To evaluate progression-free survival and relapse-free survival at 1 year with', 'concurrent chemotherapy radiation treatment combined with avelumab.', '2.3', 'Correlative Research', '2.31', 'To explore biomarkers that may predict response to avelumab in the muscle', 'invasive population. The following markers will be tested:', 'Expression of PD-L1 and CD8 by immunohistochemistry (IHC)', 'Expression of immune signatures by RNA-sequencing (RNA-seq).', 'To evaluate the association of tumor mutational burden with response to', 'concurrent chemo- radiation and immunotherapy', 'To evaluate whether concurrent chemoradiation and immunotherapy after', 'maximal TURBT is associated with a decrease in circulating Bim CD11a highpD-', '1tCD8+ T-cells and MDSCs.', 'Protocol Version Date: 21JUN2018']"
12,page_13,"['MC1752', '13', '3.0', 'Registration Patient Eligibility', 'For the run-in portion only, prior to discussing protocol entry with the patient, call the', 'MCCC Registration Office', 'to insure that a place on the protocol is open to', 'the patient.', '3.1', 'Registration - Inclusion Criteria', '3.11', 'Age >18 years.', '3.12', 'Histologic proof of T2-T4a NOMO (AJCC 8th edition ) with predominant', 'urothelial carcinoma. Mixed histologies are acceptable provided urothelial', 'carcinoma is the predominant histology. Small cell urothelial carcinoma is', 'excluded.', '3.13', 'Cystoscopy with maximal TURBT performed < 70 days of study registration.', 'NOTE: Both completely resectable or partially resectable tumors are eligible as', 'long as the treating urologist attempted complete resection. Exam under', 'anesthesia needs to be performed and documented.', '3.14', 'The following laboratory values obtained < 28 days prior to registration.', 'ANC 1500/mm³', 'PLT 100,000/mm³', 'Total bilirubin < 1.5 upper limit of normal (ULN)', 'Aspartate transaminase (AST) < 2.5 X ULN (<5 x ULN for patients with liver', 'involvement)', 'Alanine Aminotransferase (ALT) < 2.5 X ULN (<5 x ULN for patients with', 'liver involvement)', 'Hgb > 9 gm/dl', 'Calculated creatinine clearance must be > 30 ml/min using the Cockcroft-', 'Gault formula below:', 'Cockcroft-Gault Equation:', 'Creatinine clearance for males =', '(140-age)(weight - in kg)', '(72)(serum creatinine in mg/dL)', 'Creatinine clearance for females =', '(140-age)(weight - in kg)(0.85)', '72)(serum creatinine in mg/dL)', '3.15', 'ECOG Performance Status (PS 0, 1, 2) (Appendix I).', '3.16', 'Ability to provide informed written consent.', '3.17', 'Willing to return to enrolling institution for follow-up (during the Active', 'Monitoring Phase of the study).', '3.18', 'Life expectancy > 6 months.', '3.19', 'Negative serum pregnancy test done < 14 days prior to registration, for women of', 'childbearing potential only.', '3.2', 'Registration - Exclusion criteria', '3.21', 'Patients with locally advanced unresectable (T4b) or metastatic urothelial', 'carcinoma (N1M0-1) as assessed on baseline radiographic imaging obtained < 70', 'days prior to study registration. The required radiographic imaging includes:', 'Protocol Version Date: 21JUN2018']"
13,page_14,"['MC1752', '14', 'Abdomen/Pelvis CT or MRI scan', 'Chest x-ray or CT scan', '3.22', 'Patients with concurrent urothelial carcinoma and/or related variants anywhere', 'outside bladder', 'NOTE: Patients with history of non-invasive (Ta, Tis) upper tract urothelial', 'carcinoma that has been definitively treated with at least one post-treatment', 'disease assessment (i.e. cytology, biopsy, imaging) that demonstrates no', 'evidence of residual disease are eligible.', '3.23', 'A prior or concurrent malignancy of any other site or histology unless the patient', 'has been disease-free for > 2 years prior to registration except for:', 'non-melanoma skin cancer and/or localized prostate cancer(* T2 a or b,', 'Gleason <3+4) or carcinoma in situ of the uterine cervix which has been', 'adequately treated 2 years prior to registration', 'or undergoing active surveillance per standard-of-care management (e.g.,', 'chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason', 'score 3+4, and prostate-specific antigen [PSA]  10 mg/mL, etc.)', '3.24', 'Patients who have received the last administration of an anti-cancer therapy', 'including chemotherapy, immunotherapy, and monoclonal antibodies < 4 weeks', 'prior to registration, or who have not recovered from the side effects of such', 'therapy.', 'EXCEPTION: Except single dose intravesical chemotherapy administered after', 'TURBT.', '3.25', 'Patients who have received prior therapy with immune checkpoint inhibitors (e.g.', 'anti-PD-1, anti-PD-L1, anti-LAG3, anti-CTLA-4, anti-TIM3) or immune', 'costimulatory molecules (e.g. anti-CD137, anti-OX40, anti-GITR) directed', 'agents.', '3.26', 'Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal', 'or intra-pelvic), open biopsy or significant traumatic injury < 4 weeks prior to', 'registration, or who have not recovered from side effects of such procedure or', 'injury prior to registration.', 'NOTE: Patients who have had minor procedures (i.e. TURBT) or percutaneous', 'biopsies prior to registration are eligible.', '3.27', 'Patients with history of cirrhosis, alcoholic or non-alcoholic steatohepatitis', '(NASH), auto-immune hepatitis, or previous grade 3-4 drug-related hepatitis.', '3.28', 'Patient with history of prior solid organ or allogeneic bone marrow transplant.', '3.29', 'Clinically significant cardiac diseases, including any of the following:', 'History or presence of serious uncontrolled ventricular arrhythmias', 'Clinically significant resting bradycardia', 'Any of the following < 3 months prior to registration: myocardial infarction', '(MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG),', 'Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA),', 'Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)', 'Protocol Version Date: 21JUN2018']"
14,page_15,"['MC1752', '15', 'Uncontrolled hypertension defined by a SBP > 160 mm Hg and/or DBP >', '100 mm Hg, with or without anti-hypertensive medication(s)', '3.29a History of untreated HIV', 'NOTE: There is no requirement to screen patients for HIV. Patient with history', 'of HIV infection are allowed if on effective HAART therapy and CD4 count', 'more than 250.', '3.29b', 'History of active hepatitis B infection', 'NOTE: There is no requirement to screen patients for hepatitis B', '3.29c History of active hepatitis C infection', 'NOTE: There is no requirement to screen patients for hepatitis C', '3.29d Known diagnosis of any condition (i.e. post-hematopoietic or organ transplant,', 'rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease,', 'etc.) that requires chronic immunosuppressive therapy.', 'NOTE: Usage of non-steroidal anti-inflammatory medications (NSAIDS) for the', 'treatment of osteoarthritis and uric acid synthesis inhibitors for the treatment of', 'gout are permitted. For questions, please consult the study chair.', '3.29e Other concurrent severe and/or uncontrolled concomitant medical conditions', '(e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause', 'unacceptable safety risks or compromise compliance with the protocol', '3.29f Pregnant or breast-feeding women', '3.29g Women of child-bearing potential, who are biologically able to conceive, and not', 'employing two forms of highly effective contraception. Highly effective', 'contraception must be used throughout the trial and up to 8 weeks after the last', 'dose of study drug (e.g. male condom with spermicidal; diaphragm with', 'spermicide; intra-uterine device). Women of child-bearing potential, defined as', 'sexually mature women who have not undergone a hysterectomy or who have not', 'been naturally postmenopausal for at least 12 consecutive months (i.e., who has', 'had menses any time in the preceding 12 consecutive months), must have a', 'negative serum pregnancy test 14 days prior to registration.', '3.29h', 'Fertile males not willing to use contraception, as stated above', '3.29i', 'Patients unwilling or unable to comply with the protocol', '3.29j', 'Receiving any other investigational agent which would be considered as a', 'treatment for the primary neoplasm.', '3.29k', 'Known prior severe hypersensitivity to investigational product or any component', 'in its formulations, including known severe hypersensitivity reactions to', 'monoclonal antibodies (NCI CTCAE v5.0 Grade > 3)', 'Protocol Version Date: 21JUN2018']"
15,page_16,"['MC1752', '16', '4.0', 'Test Schedule', 'Active Monitoring Phase', 'C4-C10', 'End of', '6 Mo after', 'EOS', '<70', 'Screening', '(D43, D57,', 'Treatment', 'registratio', '9 Mo after', '(12 Mo after', 'days', '(28 days', 'D71, D85,', '(30 days', 'n', 'registration', 'registration)', 'Tests and', 'prior', 'prior to', 'C1', 'C2', 'C3', 'D99, D113,', 'after last', '(Clinical', '(Clinical', '(Clinical', 'procedures', 'to reg', 'reg)', '(D1)', '(D15)', '(D29)', 'D127)', 'dose)', 'Follow-up)', 'Follow-up)', 'Follow-up)', 'Window', '3 days', '3 days', '3 days', '3 days', '14 days', '14 days', '14 days', 'Maximal', 'TURBT/EU', 'X', 'A', 'History and', 'Physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Exam', 'Vital Signs,', 'Weight and', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'ECOG PS', 'Height', 'X', 'Pregnancy test', 'X¹', '(serum)', 'Pregnancy test', 'X', 'X', 'X', '(urine) 1', 'Adverse event', 'assessment/', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Toxicity', 'notation4', 'Conmeds', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Disease', 'assessment:', 'CT/MRI', 'X', 'X³', 'X', 'X', 'X', 'abdomen/', 'pelvis', '8', 'Chest CT8', 'X', 'X3', 'X', 'X', 'X', 'ECG R', 'X', 'Hematology²', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Protocol Version Date: 21JUN2018']"
16,page_17,"['MC1752', '17', 'Active Monitoring Phase', 'C4-C10', 'End of', '6 Mo after', 'EOS', '<70', 'Screening', '(D43, D57,', 'Treatment', 'registratio', '9 Mo after', '(12 Mo after', 'days', '(28 days', 'D71, D85,', '(30 days', 'n', 'registration', 'registration)', 'Tests and', 'prior', 'prior to', 'C1', 'C2', 'C3', 'D99, D113,', 'after last', '(Clinical', '(Clinical', '(Clinical', 'procedures', 'to reg', 'reg)', '(D1)', '(D15)', '(D29)', 'D127)', 'dose)', 'Follow-up)', 'Follow-up)', 'Follow-up)', 'Window', '3 days', '3 days', '3 days', '3 days', '14 days', '14 days', '14 days', 'Blood-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'chemistries6', 'X', 'Free T4 and', 'X', 'X7', 'X¹', 'X7', 'TSH', 'Urine cytology', 'X', 'X', 'X', 'X', 'Urodynamic', 'X5', 'XR', 'study', 'Bladder Biopsy', 'X', 'X', 'Cystoscopy', 'X', 'X', 'X', 'X', 'QOL forms¹', 'X', 'X', 'X', 'Optional', 'Research', 'specimens', 'per IRB 16-', '0052609', 'Optional', 'Archived', 'research', 'tissue', 'specimens', '10,R', 'Cycle = 14 days All tests and procedures are clinically indicated, unless noted with an R to indicate funding by research', '1. For women of childbearing potential only. Serum must be performed <14 days prior to registration', '2. CBC with differential', '3.', 'Abdomen, pelvis, chest CT/MRI to be done at C7(Day 85) +/- 7 days', '4. Adverse event/Toxicity notation to be done WEEKLY during radiation treatment', '5. Uroflow/post void residual; not required to be done prior to registration; however, if done then data will be collected.', '6.', 'Blood chemistries: Comprehensive Metabolic Panel (CMP) {Albumin, Bilirubin(total) Calcium, Carbon dioxide', 'Protocol Version Date: 21JUN2018']"
17,page_18,"['MC1752', '18', '(bicarbonate), Chloride, Creatinine, Glucose, Phosphatase alkaline, Potassium, Protein (total), Sodium, Transferase aspartate', 'amino(AST) (SGOT), Transferese alanine amino (ALT) (SGPT), Urea nitrogen (BUN} and Mg prior to each avelumab dose,', 'at end of study visit, and 30 days post-treatment safety follow-up', '7. Free T4 and TSH at least every 8 weeks during treatment (Collect at same time as treatment related labs). Also collect at end', 'of study or 30 days post-treatment safety follow-up (if not performed in the previous 8 weeks)', '8. With contrast preferred; however if treating Provider determines that contrast is contraindicated then contrast can be omitted.', '9. NOTE: Participants sign a separate consent for IRB 16-005260', '10. Archived tissue per section 17.0', '11. EORTC QLQ-C30 (Appendix II) and EORTC QLQ-BLM30 (Appendix III). Booklets are to be used', 'for', 'this', 'study.', 'R Research funded (see Section 19.0)', '4.1', 'Survival Follow-up', 'This study does not involve survival follow-up. Patients are considered off study 12 months after registration.', 'Protocol Version Date: 21JUN2018']"
18,page_19,"['5.0', 'Grouping Factor:', 'Study Stage:', '1 1=Safety Run-in VS 2=Expansion portion', '6.0', 'Registration Procedures', '6.1', 'Safety Run-In', 'Prior to discussing protocol entry with the patient, call the MCCC Registration Office', 'to insure that a place on the protocol is open to the patient.', 'To register a patient, fax', ')', 'a completed eligibility checklist to the Mayo Clinic', 'Cancer Center (MCCC) Registration Office between 8 a.m. and 4:30 p.m. central time Monday', 'through Friday.', '6.2', 'Registration, following the completion of run-in portion:', '6.21', 'Registering a patient', 'To register a patient, access the Mayo Clinic Cancer Center (MCCC) web page and enter', 'the registration/randomization application. Theregistration/ randomization application is', 'available 24 hours a day, 7 days a week. Back up and/or system support contact', 'information is available on the website. If unable to access the website, call the MCCC', 'Registration Office at', 'between the hours of 8 a.m. and 4:30 p.m. Central', 'Time (Monday through Friday).', 'The instructions for the registration/randomizatio application are available on the', 'MCCC web page', ')', 'and detail the process for', 'completing and confirming patient registration. Prior to initiation of protocol treatment,', 'this process must be completed in its entirety and an MCCC subject ID number must be', 'available as noted in the instructions. It is the responsibility of the individual registering', 'the patient to confirm the process has been successfully completed prior to release of the', 'study agent. Patient registration via the registration/randomizatior application can be', 'confirmed in any of the following ways:', 'Contact the MCCC Registration Office', 'If the patient was fully', 'registered, the MCCC Registration Office staff can access the information from', 'the centralized database and confirm the registration.', 'Refer to ""Instructions for Remote Registration"" in section ""Finding/Displaying', 'Information about A Registered Subject.""', '6.3', 'Verification of materials', 'Prior to accepting the registration, registration/randomization application will verify the', 'following:', 'IRB approval at the registering institution', 'Patient eligibility', 'Existence of a signed consent form', 'Existence of a signed authorization for use and disclosure of protected health information', '6.4', 'Documentation of IRB approval', 'Documentation of IRB approval must be on file in the Registration Office before an investigator', 'may register any patients.', 'In addition to submitting initial IRB approval documents, ongoing IRB approval documentation', 'must be on file (no less than annually) at the Registration Office (fax:', '). If the', 'necessary documentation is not submitted in advance of attempting patient registration, the', 'registration will not be accepted and the patient may not be enrolled in the protocol until the', 'situation is resolved.']"
19,page_20,"['MC1752', '20', 'When the study has been permanently closed to patient enrollment, submission of annual IRB', 'approvals to the Registration Office is no longer necessary.', '6.5', 'Correlative Research', '6.42', 'Optional', 'An optional correlative research component is part of this study, there will be an option to', 'select if the patient is to be registered onto this component (see Section 17.0).', 'Patient has/has not given permission to give his/her tissue sample for research testing.', '6.6', 'Treatment on protocol', 'Treatment on this protocol must commence at Mayo Clinic under the supervision of a medical', 'oncologist or radiation oncologist', '6.7', 'Treatment start', 'Treatment cannot begin prior to registration and must begin <7 days after registration.', '6.8', 'Pretreatment', 'Pretreatment tests/procedures (see Section 4.0) must be completed within the guidelines specified', 'on the test schedule.', '6.9a', 'Baseline symptoms', 'All required baseline symptoms (see Section 10.6) must be documented and graded.', '6.9b', 'A radiation oncologist has seen the patient and confirms the patient is a suitable candidate', 'for this study.', '6.9c', 'Study drug', 'Study drug is available on site.', '6.9d', 'Patient questionnaire booklets', 'Patient questionnaire booklets are available on site. Copies are not acceptable for these', 'submissions. Booklets should be ordered using the Patient Questionnaire Order Form', 'Protocol Version Date: 21JUN2018']"
20,page_21,"['MC1752', '21', '6.9e', 'Study Conduct', 'The clinical trial will be conducted in compliance with regulations (21 CFR 312, 50, and 56),', 'guidelines for Good Clinical Practice (ICH Guidance E6), and in accordance with general ethical', 'principles outlined in the Declaration of Helsinki; informed consent will be obtained from all', 'participating patients; the protocol and any amendments will be subject to approval by the', 'designated IRB prior to implementation, in accordance with 21 CFR 56.103(a); and subject', 'records will be stored in a secure location and subject confidentiality will be maintained. The', 'investigator will be thoroughly familiar with the appropriate use of the study drug as described in', ""the protocol and Investigator's Brochure. Essential clinical documents will be maintained to"", 'demonstrate the validity of the study and the integrity of the data collected. Master files should be', 'established at the beginning of the study, maintained for the duration of the study and retained', 'according to the appropriate regulations.', 'Protocol Version Date: 21JUN2018']"
21,page_22,"['MC1752', '22', '7.0', 'Protocol Treatment', 'Safety Run-in', 'The first 6 patients enrolled will be included in the safety run-in portion following the treatment schedule', 'included below (section 7.1). Patients will be treated for the first two cycles with avelumab only.', 'Chemoradiation will begin at cycle 3 (Day 29). This will be performed to determine whether or not the', 'proposed concurrent chemotherapy radiation treatment combined with avelumab is a safe regimen.', 'ACCRUAL WILL BE TEMPORARILY HALTED between the safety run-in and expansion portion in', 'order to evaluate the concurrent radiation therapy adverse event data. This data will be reviewed by the', 'Study Chair and Study Statistician.', '7.1', 'Treatment Schedule', '7.11', 'Drug Treatment schedule - Use actual weight or estimated dry weight if fluid retention.', ""Chemotherapy choice is based on treating provider's discretion."", '7.12', 'For both cohorts: Avelumab 10mg/kg doses prior to initiation of concurrent chemo-', 'radiation therapy. The treatment will continue for 10 total doses.', '7.13', 'Avelumab should be administered in a setting that allows for immediate access to an', 'intensive care unit or equivalent environment and administration of therapy for', 'anaphylaxis, such as the ability to implement immediate resuscitation measures. Steroids', '(dexamethasone 10mg), epinephrine (1:1,000 dilution), allergy medications (IV', 'antihistamines), bronchodilators, or equivalents, and oxygen should be available for', 'immediate access.', 'Patients must be observed for 30 mins post avelumab infusion for potential related', 'reactions', '7.14', 'Premedication', 'Premedicate patients with an antihistamine and with acetaminophen', '(acetaminophen 650 mg ) PO and diphenhydramine 25-50 mg PO X 1 prior to the first 4', 'infusions of avelumab. Premedication', 'should be administered for subsequent avelumab doses based upon clinical judgement', 'and presence/severity of prior infusion reactions.', 'Protocol Version Date: 21JUN2018']"
22,page_23,"['MC1752', '23', '7.15', 'Treatment Medication safety run-in and expansion portions', ""NOTE: cohort selection is treating provider's choice"", 'Cohort', 'Agent', 'Dose', 'Route', 'Day', 'Infusion', 'time', 'Over 60', '1 & 2', 'IV', 'Q2weeks for a total of', 'minutes', 'Avelumab', '10mg/kg', '10doses(cycles)', '(+/-', '10minutes)', 'Continuous', 'IV infusion', 'Day1-5 and Day 16-20 of RT.', 'Per', '500', '1', '5-FU', 'via', 'Please note that the infusion', 'standard of', 'mg/m2/day', 'ambulatory', 'is based on day on RT.', 'care', 'pump', 'Mitomycin', '1', '1 cycle only. Starting on', 'C', '12 mg/m2', 'IV push', 'N/A', 'C3D1 (Day 29)', 'Starting on C3-5,D1 (Day 29)', 'Per', '35', 'and continue weekly for up to', '2', 'Cisplatin', 'IV', 'standard of', 'mg/m2/day', '6 weeks. If hypofractionated', 'care', 'RT is used then cisplatin will', 'finish early.', ""NOTE: cohort selection is treating provider's choice"", 'A maximum of 2 doses of 5-FU and one dose of mitomycin (MMC) or 6 weekly cycles of', 'cisplatin will be administered based on the above schedule. A maximum of 10 cycles of', 'avelumab immunotherapy will be administered in both Cohort 1 and Cohort 2. If a', 'hypofractionated schedule of RT is used then cisplatin therapy will be stopped early with', 'completion of RT.', 'Dosage for all the chemotherapy and immunotherapy regimens is based on approved FDA dosing', 'schedules.', 'All cycles will be based on avelumab given once every 14 days.', 'Chemo and radiation therapy may be given as clinically indicated and any delays are per treating', ""provider's discretion. Such delays do not affect the cycle length of avelumab."", 'Patients must be observed for 30 mins post avelumab infusion for potential related', 'reactions.', 'Protocol Version Date: 21JUN2018']"
23,page_24,"['MC1752', '24', 'Avelumab dosing:', 'To account for drug quantities supplied within each vial and to minimize wasted unused', 'investigational drug, pharmacy may adjust the calculated drug dose +/- 10% for each patient. All', 'patients dosed within these parameters will be considered dosed at full dose.', 'Definition of an Overdose for Avelumab used in this protocol:', 'Patients dosed > 10% above their calculated drug dose will be considered over-dosed.', '7.2', 'Radiation Therapy', 'NOTE: Protocol defined radiation treatment is planned to begin at C3D1 (D29 of', 'overall study) (+/-7 days)', 'NOTE: Protocol radiation simulation can begin before or after registration in', 'anticipation to start radiation C3D1 (D29 of overall study) (+/-7 days)', '7.21', 'Radiation Dose', '7.211 Doses throughout will be prescribed in Gy for the IMRT. Total dose will be 64', 'Gy (in 2 Gy; or 55 Gy in 2.75Gy(RBE)/Gy, for 5 fractions per week. The D95%', 'of the PTV1 should receive the prescription dose. The minimum dose to the', 'OTV1 or PTV1 should be 90% of the prescription dose.', '7.212', 'For prescription purposes D95% of the PTV2 shall receive >80% of the', 'prescription. Minimum dose to the PTV2 or OTV 2 will be >70% of the', 'prescription.', '7.213 Prescription dose to the PTV shall be according to the following schema', 'delivered in 2 Gy per fraction or 2.75 Gy per fraction. in consecutive fractions', 'Monday-Friday for a total of 20 treatments or 32 treatments based on the', 'radiation regimen chosen by the physician.', '7.215', 'Volumes:', 'CTV 1 = GTV including intra-vesical or extra-vesical tumor + tumor', 'bed resection area.', 'PTV 1 = CTV1+8mm', 'CTV 2 = CTV 1 + bladder + bladder neck', 'PTV 2= CTV 2 +8mm', '7.22', 'Equipment and Physical Factors', 'Radiation will be delivered using the available x-ray equipment', 'Protocol Version Date: 21JUN2018']"
24,page_25,"['MC1752', '25', '7.23', 'Localization and Imaging Requirements', 'Localization: Proper localization of the appropriate target volumes requires', 'reproducible immobilization and correlation of imaging studies. Planning CT', 'scans will be performed using a high-resolution scanner with <2 mm cuts', 'through the region of interest (bladder), and at least 5mm elsewhere in the pelvis.', ""MRI will also be considered appropriate for structures' definition."", 'MRI of the pelvis and bladder can be used for treatment planning volume delineation. T2', 'sequence 3D with VI 2mm spacing is recommended.', 'If PET scan was done prior to the TURBT it can be used to help define the CTV1.', 'Immobilization: Patients will be immobilized for the treatment in a', 'supine or prone position, using an appropriately customized', 'immobilization device.', 'Treatment: Patients will be encouraged to undergo treatment with an', 'empty bladder and an empty bowel. Close fitting devices as used for', 'simulation will be used for daily treatments.', 'Daily position verification: Patients will be setup with lasers in a custom fitting device.', 'Patient orientation will be verified based on skin marks. Daily bladder position will then', 'be verified based on volumetric guidance employing the techniques described below.', '7.24', 'On-line Daily Correction', 'We do realize that for an individual patient bladder movement and set up error may be', 'non-parametric and a large random component may be present. Thus, several different', 'volumetric image guidance modalities may be used.', '7.25', 'Error Verification', '3D volumetric guidance: cone beam CT, CT on rails, MRI, or other means of 3D', 'guidance can be employed.', '7.25 Critical Normal Structures', 'Gross tumor volume: will include any intravescal or extravesical tumor', 'Clinical Target Volume.', 'CTV1: It would consist of GTV + tumor bed. All imaging modalities and information', 'available should be used to define the extend of the disease. If not clinically', 'contraindicated an MRI T2 cube can be used to aid define the gross tumor volume and', 'resection area (tumor bed).', 'CTV2: It would consist of CTV1 + bladder + bladder neck', 'Rectum: is defined from the ischial tuberosities to the sigmoid flexure.', 'Small bowel: is defined by the small bowel in contact with the bladder. It should be', 'contoured including 2 cm above the treatment field', '7.27', 'Normal Tissue Constraints (NTC)', 'Normal tissue constraints (NTC) to define dose.', 'Protocol Version Date: 21JUN2018']"
25,page_26,"['MC1752', '26', 'Table 2a. Standard-fractionation', 'Structure', 'Constraint', 'Minor deviation', 'Major deviation', 'PTV1', 'D95%=100', '<99%', '<96%', 'Min >90%', '<90%', '<85%', 'Dmax <108%', '>108%', '>110%', 'PTV 2', 'D95=>80%', '<80%', '<75%', 'Min >70%', '<70%', '<65%', 'Rectum', 'V90% <35%', 'Femoral heads', 'V45 <1 cc', 'V45 <2 cc', 'V45 > 2cc', 'Small bowel', 'Dmax <105%', '100% <10cc', 'The maximum dose without a major deviation will be used for treatment.', 'Normal tissue volumes', 'Rectum: is defined inferiorly from the ischial tuberosities and superiorly', 'to the sigmoid flexure.', 'Small bowel: Individual loops should be contoured including 3 cm above', 'and below the target or targets.', 'Femoral Heads: Countered to the level of the lesser trochanter.', '7.28 Quality Assurance (Physics check)', 'Physicist team at each site is responsible for quality assurance. This is', 'per standard of care', 'Daily online volumetric imaging will be used. Soft tissue matching will', 'be done. If fiducials are available they can be used to as a verification', 'aid.', 'Coronal, transverse, and sagittal CT slices with overlaid doses', 'representing the total dose to be delivered should be available.', 'Dose volume histograms (DVH) including, but not limited to, bladder,', 'bladder wall, femoral heads, and rectal wall will be available.', 'If available, different imaging and biologic-imaging studies can be used', 'to define different structures. DVH will be performed as needed.', '7.29a Treatment Interruptions', 'Treatment should be delivered over 20 or 32 consecutive treatments. Unplanned', 'interruptions, consecutive or not, for more than 5 treatment days (Monday-Friday) are not', 'allowed. Treatment breaks > 5 days are considered major deviations and not allowed. If', 'treatment interruptions of 5 days or longer are not of medical necessity, arrangements To', 'Protocol Version Date: 21JUN2018']"
26,page_27,"['MC1752', '27', 'continue treatment should be done. Major treatment deviations will not exclude patient', 'from the trial or for data analysis.', 'Treatments should be planned to be delivered on consecutive days, Monday to Friday.', '7.29b Radiation Toxicity', 'The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from the National', 'Cancer Institute (NCI) will be used for toxicity grading. All patients will be seen weekly', 'by the radiation oncologist during radiation therapy. Any observations regarding radiation', 'reactions will be recorded and should include attention toward the following potential side', 'effects:', 'Rectal irritation manifesting as diarrhea, rectal incontinence, proctitis or rectal', 'bleeding.', 'Bladder toxicity including urinary frequency/urgency, dysuria, hematuria,', 'obstruction, retention and incontinence.', 'Presence or absence of erections sufficient for sexual activity and use of', 'medications or mechanical aids to enhance erections should be recorded.', 'Clinical discretion may be exercised to treat side effects from radiation therapy.', '8.0', 'Dosage Modification Based on Adverse Events', 'The following modifications are suggestions but the treating provider is advised to use clinical judgement', 'in dose modifications keeping in mind safety of the patients.', 'Dose Limiting Toxicity Definition', 'While dose limiting toxicity (DLT) is commonly defined by specified toxicities that occur during cycle 1', 'of therapy, within this trial the timeframe for DLT evaluation will include the entire duration of CRT', 'therapy (date of first radiation fraction administration to date of last radiation fraction administration) to', 'coincide with completion of a standard bladder-sparing CMT schedule in which radiation is administered', 'once daily during weekdays for 20-32 fractions (treatments).', 'As standard bladder-sparing CMT is known to produce grade 1-2 TRAEs in nearly all patients and grade', '3-4 Treatment-related adverse events (TRAEs) in 35% of patients, treatment related toxicity is expected', '[2, 4]. With standard CMT, however, immune related adverse events (irAEs) are not observed.', 'Therefore, in evaluating safety of the new avelumab containing CMT treatment approaches within this', 'protocol, severe irAEs or non-immune TRAEs which compromise the ability to deliver CMT are of', 'particular interest. Accordingly, DLT during the safety run-in portion of the protocol will be defined', 'as the following:', 'a) Prolonged grade 2 (lasting more than 21 days) or higher irAEs including (hypophysitis, uveitis,', 'hepatitis, and colitis).', 'NOTE: Treatment related hypothyroidism that is successfully treated with levothyroxine oral', 'supplementation and does not cause a treatment delay in radiation by > 21 days is not considered a DLT', 'event. In the case of suspected irAEs, diagnostic confirmation (supporting labs, imaging, biopsies, etc.)', 'should be provided in all reports.', 'Protocol Version Date: 21JUN2018']"
27,page_28,"['MC1752', '28', 'b) Grade 2 or higher non-immune TRAEs which cause a delay in radiation therapy by > 21 days.', 'c) Any grade myocarditis', 'd) Grade 2 pneumonitis', 'ALERT:', 'ADR reporting may be required for some adverse events (See Section 10.0)', '<', '8.1', 'Dose Levels (Based on Adverse Events in Tables 8.2 and 8.3)', 'Do', 'se', 'Le', 'vel', 'Cisplatin **', '5-FU**', 'Mitomycin**', 'Avelumab', '1*', '35mg/m2', '500mg/m2', '12mg/m2', '10 mg/m2', 'No dose', 'No dose', '-1', '28mg/m2', '400mg/m2', 'reductions', 'reductions', 'No dose', 'No dose', 'No dose', '-2', '20mg/m2', 'reductions', 'reductions', 'reductions', '*Dose level 1 refers to the starting dose.', '**Cisplatin, 5-FU, Mitomycin: these are suggested dose levels and are only a guideline', 'Use the NCI Common Terminology Criteria for Adverse Events (CTCAE) current version 5.0* unless', 'otherwise specified <<', 'Located at http:/ctep.cancer.gov/protocolDevelopment/electronic applications.ctc.htm', 'General guidance for dose modifications and treatment delays and discontinuation', 'Due to the prolonged half-life associated with monoclonal antibodies, no dose reductions of avelumab are', 'planned.', 'If participant has any grade 3 toxicity with the chemotherapy or immunotherapy, radiation can still continue if', 'considered safe by the treating provider. If all therapy is stopped including chemotherapy, immunotherapy and', 'radiation then patient will be followed as per the routine follow up for one year.', 'Protocol Version Date: 21JUN2018']"
28,page_29,"['MC1752', '29', '8.2', 'Dose Modification Guidelines for Drug-Related Adverse Events for Avelumab', 'Omit = The current dose(s) for the specified drug(s) during a cycle is skipped. The patient does', 'not make up the omitted dose(s) at a later time.', 'Hold/Delay = The current dose(s) of all drugs during a cycle is delayed. The patient does make', 'up the delayed dose(s) when the patient meets the protocol criteria to restart drugs.', 'Discontinue = The specified drug(s) are totally stopped.', 'NOTE: If anvelumab therapy is delayed for more than 28 days then discontinue avelumab therapy', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Gastrointestinal Disorders', 'Diarrhea/Colitis', 'Grade 1', 'Continue and initiate supportive care per Section 9.0', 'Delay avelumab therapy', 'If improves to Grade < 1:', 'Resume avelumab therapy', 'Diarrhea/Colitis', 'During radiation therapy: If persists > 5-7 days or recurs:', 'Grade 2', 'Treat as Grade 3 or 4.', 'Outside radiation therapy: If persists > 14 days or recurs', 'Discontinue avelumab.', 'Continue and initiate supportive care per Section 9.0', 'Delay avelumab for Grade 3.', 'Permanently discontinue avelumab for Grade 4 or recurrent', 'Grade 3.', 'Continue and initiate supportive care per Section 9.0', 'If improves:', 'Diarrhea/Colitis', 'Continue steroids until Grade < 1, then taper over at least 1', 'Grade 3 to 4', 'month; resume avelumab therapy following steroids taper (for', 'initial Grade 3).', 'If worsens, persists > 3 to 5 days, or recurs after improvement:', 'Add infliximab 5mg/kg (if no contraindication). Note:', 'infliximab should not be used in cases of perforation or sepsis.', 'Skin and subcutaneous tissue', 'Continue and initiate supportive care per Section 9.0', 'disorders', 'If persists > 1 to 2 weeks or recurs:', 'Delay avelumab therapy', 'Consider skin biopsy', 'Consider 0.5-1mg/kg/day prednisone or equivalent. Once', 'Rash acneiform', 'improving, taper steroids over at least 1 month, consider', 'Grade 1 to 2', 'prophylactic antibiotics for opportunistic infections, and', 'resume avelumab therapy following steroids taper.', 'If worsens:', 'Treat as Grade 3 to 4.', 'Protocol Version Date: 21JUN2018']"
29,page_30,"['MC1752', '30', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Delay avelumab for Grade 3.', 'Permanently discontinue for Grade 4 or recurrent Grade 3.', 'Consider skin biopsy', 'Dermatology consult', 'Rash acneiform', '1 to 2 mg/kg/day prednisone or equivalent', 'Grade 3 to 4', 'Add prophylactic antibiotics for opportunistic infections', 'If Grade 3 improves to Grade 1:', 'Taper steroids over at least 1 month; resume avelumab therapy', 'following steroids taper (for initial Grade 3).', 'If persists > 1 to 2 weeks or recurs:', 'Delay avelumab therapy', 'Consider skin biopsy', 'Consider 0.5-1 mg/kg/day prednisone or equivalent. Once', 'improving, taper steroids over at least 1 month, consider', 'Rash maculo-papular', 'Grade 1 to 2', 'prophylactic antibiotics for opportunistic infections, and', 'resume avelumab therapy following steroids taper.', 'If worsens:', 'Treat as Grade 3 to 4.', 'Delay avelumab for Grade 3.', 'Permanently discontinue for Grade 4 or recurrent Grade 3.', 'Consider skin biopsy', 'Dermatology consult', 'Rash maculo-papular', '1 to 2 mg/kg/day prednisone or equivalent', 'Grade 3 to 4', 'Add prophylactic antibiotics for opportunistic infections', 'If Grade 3 improves to Grade < 1:', 'Taper steroids over at least 1 month; resume avelumab therapy', 'following steroids taper (for initial Grade 3).', 'General disorders and', 'Infusion-related reaction', 'administration site conditions', 'Grade 1', 'Decrease the avelumab infusion rate by 50% and', 'Mild transient reaction; infusion', 'monitor closely for any worsening', 'interruption not indicated;', 'intervention not indicated', 'Infusion-related reaction', 'Temporarily discontinue avelumab infusion', 'Grade 2', 'Resume infusion at 50% of previous rate once infusion-', 'Therapy or infusion interruption', 'related reaction has resolved or decreased to at least Grade', 'indicated but responds promptly', '1 in severity, and monitor closely for any worsening', 'to symptomatic treatment (for', 'Once the avelumab infusion rate has been decreased by 50% or', 'example, antihistamines,', 'interrupted due to an infusion-related reaction, it must remain', 'NSAIDs, narcotics, iv fluids);', 'decreased for all subsequent infusions. If the subject has a', 'prophylactic medications', 'second infusion-related reaction Grade > 2 on the slower', 'indicated for < 24 h', 'infusion rate, the infusion should be stopped and the subject', 'should be removed from avelumab treatment.', 'Protocol Version Date: 21JUN2018']"
30,page_31,"['MC1752', '31', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Infusion-related reaction', 'Grade 3 or Grade 4', 'Grade 3: Prolonged (for', 'example, not rapidly', 'responsive to', 'Stop the avelumab infusion immediately and', 'symptomatic medication', 'disconnect infusion tubing from the subject', 'and/or brief interruption', 'Subjects have to be withdrawn immediately from', 'of infusion); recurrence', 'avelumab treatment and must not receive any further', 'avelumab treatment', 'of symptoms following', 'initial improvement;', 'All Grade 3 or 4 infusion reactions should be', 'hospitalization indicated', 'reported within 24 hours to EMD Serono and', 'for clinical sequelae', 'reported as an SAE if criteria are met.', 'Grade 4: Life-threatening', 'consequences; urgent', 'intervention indicated', 'Investigations', 'Aspartate aminotransferase', 'increased', 'or Alanine aminotransferase', 'increased', 'Continue avelumab therapy', 'Bilirubin increased', 'Continue liver function monitoring', 'If worsens:', 'Grade 1', 'Treat as Grade 2 or 3 to 4.', 'AST or ALT > ULN to 3.0 X', 'ULN and/or Total bilirubin >', 'ULN to 1.5 X ULN', 'Aspartate aminotransferase', 'increased', 'or Alanine aminotransferase', 'Delay avelumab therapy', 'increased', 'Increase frequency of monitoring to every 3 days.', 'Bilirubin increased', 'If returns to Grade VI 1:', 'Resume routine monitoring; resume avelumab therapy.', 'Grade 2', 'If elevation persists > 5 to 7 days or worsens:', 'AST or ALT > 3.0 to VI 5 X ULN', 'Treat as Grade 3 to 4.', 'and/or total bilirubin > 1.5 to < 3', 'x ULN', 'Aspartate aminotransferase', 'Permanently discontinue avelumab therapy', 'increased', 'Increase frequency of monitoring to every 1 to 2 days', 'or Alanine aminotransferase', '1 to 2 mg/kg/day prednisone or equivalent', 'increased', 'Bilirubin increased', 'Add prophylactic antibiotics for opportunistic infections', 'Consult gastroenterologist/ hepatologist', 'Consider obtaining MRI/CT scan of liver and liver biopsy if', 'Grade 3 to 4', 'clinically warranted', 'AST or ALT > 5 X ULN and/or', 'total bilirubin > 3 X ULN', 'Continue avelumab therapy', 'Grade 1', 'Continue renal function monitoring', 'Creatinine increased > ULN to', 'If worsens:', '1.5 X ULN', 'Treat as Grade 2 to 3 or 4.', 'Protocol Version Date: 21JUN2018']"
31,page_32,"['MC1752', '32', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Delay avelumab therapy', 'Increase frequency of monitoring to every 3 days', 'Continue and initiate supportive care per Section 9.0', 'Consider renal biopsy', 'Grade 2 to 3', 'If returns to Grade <1:', 'Creatinine increased > 1.5 and', '6 x ULN', 'Taper steroids over at least 1 month, and resume avelumab', 'therapy following steroids taper.', 'If worsens:', 'Treat as Grade 4.', 'Permanently discontinue avelumab therapy', 'Monitor creatinine daily', '1 to 2 mg/kg/day prednisone or equivalent.', 'Grade 4', 'Add prophylactic antibiotics for opportunistic infections', 'Creatinine increased > 6 x ULN', 'Consider renal biopsy', 'Nephrology consult', 'If returns to Grade 1:', 'Taper steroids over at least 1 month.', 'Cardiac disorders', 'Myocarditis', 'New onset of cardiac signs or', 'symptoms and / or new', 'laboratory cardiac biomarker', 'Permanently discontinue avelumab.', 'elevations (e.g. troponin, CK-', 'MB, BNP) or cardiac imaging', 'abnormalities suggestive of', 'myocarditis.', 'Permanently discontinue avelumab.', 'Guideline based supportive treatment as appropriate as per', 'cardiology consult.*', '1 to 2 mg/kg/day prednisone or equivalent', 'Immune-mediated myocarditis', 'Add prophylactic antibiotics for opportunistic infections.', 'Once improving, taper steroids over at least 1 month.', 'If no improvement or worsening, consider additional', 'immunosuppressants (e.g. azathioprine, cyclosporine A).', 'Respiratory, thoracic and', 'Consider delaying avelumab therapy', 'mediastinal disorders', 'Monitor for symptoms every 2 to 3 days', 'Consider Pulmonary and Infectious Disease consults', 'Pneumonitis', 'Re-assess at least every 3 weeks', 'Grade 1', 'If worsens:', 'Treat as Grade 2 or Grade 3 to 4.', 'Protocol Version Date: 21JUN2018']"
32,page_33,"['MC1752', '33', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Permanently discontinue avelumab therapy.', 'Pneumonitis', 'Pulmonary and Infectious Disease consults.', 'Grade 2 or higher', 'Continue and initiate supportive care per Section 9.0', 'Endocrine Disorders', 'Continue avelumab therapy', 'Endocrinology consult if needed', 'Grade 1 endocrinopathies', '(hypothyroidism,', 'Continue and initiate supportive care per Section 9.0', 'hyperthyroidism, adrenal', 'Rule-out secondary endocrinopathies (i.e. hypopituitarism /', 'insufficiency, type I diabetes', 'hypophysitis)', 'mellitus)', 'Follow-up Management: Continue hormone', '(replacement/suppression: and monitoring of endocrine function', 'as appropriate.', 'Permanently discontinue avelumab therapy', 'For Grade 3 or 4 consider hospitalization', 'Endocrinology consult', 'Grade 2, Grade 3 or Grade 4', 'endocrinopathies', '(hypothyroidism,', 'If secondary thyroid and/or adrenal insufficiency is confirmed', 'hyperthyroidism, adrenal', '(i.e. subnormal serum FT4 with inappropriately low TSH', 'insufficiency, type I diabetes', 'and/or low serum cortisol with inappropriately low ACTH) :', 'mellitus)', 'Refer to endocrinologist for dynamic testing as indicated', 'Grade 2, Grade 3 or Grade 4', 'and measurement of other hormones (FSH, LH, GH/IGF-1,', 'hypopituitarism/Hypophysitis', 'PRL, testosterone in men, estrogens in women)', '(secondary endocrinopathies)', 'Hormone replacement/suppressive therapy as appropriate', 'Perform pituitary MRI and visual field examination as', 'indicated', 'Other Immune Related', 'Delay avelumab therapy pending clinical investigation', 'Adverse Events (irAEs) (not', 'Grade 2 or Grade 3 clinical', 'If irAE is ruled out, manage as appropriate according to the', 'described above)', 'signs or symptoms suggestive', 'diagnosis and consider re-starting avelumab therapy', 'of a potential irAE', 'If irAE is confirmed, treat as Grade 2 or 3 irAE.', 'Delay avelumab therapy', '1 to 2 mg/kg/day prednisone or equivalent', 'Add prophylactic antibiotics for opportunistic infections', 'Grade 2 irAE or first', 'Specialty consult as appropriate', 'occurrence of Grade 3 irAE', 'If improves to Grade VI 1:', 'Taper steroids over at least 1 month and resume avelumab', 'therapy following steroids taper.', 'Protocol Version Date: 21JUN2018']"
33,page_34,"['MC1752', '34', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Permanently discontinue avelumab therapy', '1.0 to 2 mg/kg/day', 'prednisone or equivalent', 'Recurrence of same Grade 3', 'Add prophylactic antibiotics for opportunistic infections', 'irAEs', 'Specialty consult as appropriate', 'If improves to Grade < 1:', 'Taper steroids over at least 1 month.', 'Permanently discontinue avelumab therapy', '1.0 to 2 mg/kg/day', 'prednisone or equivalent and/or other immunosuppressant as', 'needed', 'Grade 4', 'Add prophylactic antibiotics for opportunistic infections', 'Specialty consult.', 'If improves to Grade 1:', 'Taper steroids over at least 1 month', 'Requirement for 10 mg per day', 'or greater prednisone or', 'equivalent for more than 12', 'weeks for reasons other than', 'hormonal replacement for', 'Permanently discontinue avelumab therapy', 'adrenal insufficiency', 'Specialty consult', 'Persistent Grade 2 or 3 irAE', 'lasting 12 weeks or longer', 'Abbreviations: ACTH=adrenocorticotropic hormone; ADL=activities of daily living; ALT=alanine aminotransferase;', 'AST=aspartate aminotransferase; BNP=B-type natriuretic peptide; CK-MB=creatine kinase MB; CT= computed', 'tomography; FSH=follicle-stimulating hormone; GH=growth hormone; IGF-1=insulin-like growth factor 1; irAE=immune', 'related adverse event; IV=intravenous; LH=luteinizing hormone; MRI=magnetic resonance imaging; NCI CTCAE=National', 'Cancer Institute Common Terminology Criteria for Adverse Events; PRL=prolactin;T4=thyroxine; TSH=thyroid stimulating', 'hormone; ULN=upper limit of normal.', 'NOTE: If anvelumab therapy is delayed for more than 28 days then discontinue avelumab therapy', 'Since inhibition of PD-L1 stimulates the immune system, irAEs may occur. Treatment', 'of irAEs is mainly dependent upon severity (NCI-CTCAE grade):', 'Grade 1 to 2: treat symptomatically or with moderate dose steroids, more frequent monitoring', 'Grade 1 to 2 (persistent): manage similar to high grade AE (Grade 3 to 4)', 'Grade 3 to 4: treat with high dose corticosteroids', '8.3', 'Dose Modifications for Cisplatin, 5-FU, and/or Mitomycin ( Based on Interval Adverse', 'Events (occurring within a cycle of treatment)', 'Protocol Version Date: 21JUN2018']"
34,page_35,"['MC1752', '35', 'Patients enrolled in this study will be evaluated clinically and with standard laboratory tests', 'before and at regular intervals during their participation in this study. This evaluation will', 'monitor for adverse events (all grades), serious adverse events, immune related adverse events,', 'and adverse events requiring study drug interruption or discontinuation at each study visit for the', 'duration of their participation in the study.', 'Concurrent chemo radiation is not expected to cause any immune related side effects. But since', 'the therapy is being combined with avelumab which can induce immune related side effects if', 'treating provider assessed an adverse event as immune related then it is recommended to perform', 'appropriate work up and confirming the nature of side effect.', 'It is expected to observe grade 3-4 gastrointestinal and genitourinary side effects with concurrent', ""chemo radiation. Symptom management as per best practices is recommended. It's appropriate to"", 'use growth factors for neutropenic complications.', 'CTCAE', 'System/Organ/Class', '(SOC)', 'ADVERSE EVENT', 'AGENT', 'ACTION', 'Febrile neutropenia', '(fever without', 'Delay chemotherapy by 1 week until ANC', 'clinically or', 'recovers to Grade 0-2 and until fever', 'Blood and lymphatic', 'microbiologically', 'Cisplatin', 'resolves.', 'disorders', 'documented', '5FU', 'Reduce dose by one level or more for', 'infection) [ANC', '<1.0 X 109 C/L]', 'subsequent cycles.', 'fever 38.3°C)', 'Left ventricular', 'systolic', 'Cisplatin', 'Dysfunction,', 'Grade 3 or higher hold chemotherapy until', '5FU', '.', 'myocardial', 'recovers to grade <1. .', 'Cardiac Disorders', 'infarction', 'Gastrointestinal', 'If not controlled with optimal medication.', 'Vomiting', 'Cisplatin,', 'disorders', '>Grade 3', '5FU', 'Reduce dose by one dose level and use', 'reduced level for subsequent cycles', 'Allergic reaction', 'Grade 1', 'Cisplatin ,', '5FU or', 'Stop infusion. After recovery restart the', '(eg, mild flushing,', 'infusion as per standard of care', 'Mitomycin', 'rash, pruritis)', 'Allergic reaction', 'Grade 2-3', 'Stop infusion. Give IV antihistamine', '(diphenhydramine 50 mg IV), IV H2-', 'Immune system', '(e.g. moderate rash,', 'Cisplatin ,', 'disorders', 'flushing, mild', '5FU or', 'receptor antagonist (famotidine 20 mg IV)', 'and steroid (dexamethasone 10 mg IV)', 'dyspnea, chest', 'Mitomycin', 'discomfort, mild', 'After recovery of symptoms resume', 'chemotherapy as per standard of care', 'hypotension)', 'Protocol Version Date: 21JUN2018']"
35,page_36,"['MC1752', '36', 'CTCAE', 'System/Organ/Class', '(SOC)', 'ADVERSE EVENT', 'AGENT', 'ACTION', 'Anaphylaxis', '(e.g. one or more of', 'Stop infusion. give IV antihistamine', 'the following):', '(diphenhydramine 50 mg IV), IV H2-', 'respiratory distress', 'Cisplatin,', 'receptor antagonist (famotidine 20 mg IV)', 'requiring treatment,', '5FU or', 'and steroid (dexamethasone 10 mg IV)', 'generalized urticaria,', 'Mitomycin', 'Add epinephrine or bronchodilators if', 'angioedema,', 'indicated, report as an adverse event', 'hypotension', 'Discontinue chemotherapy.', 'requiring therapy)', 'Neutrophil count', 'Delay chemotherapy by 1 week until', 'decreased', 'Cisplatin,', 'recovery to Grade 0-2', '>Grade 3 (ANC 500', '5FU', 'Consider reducing dose by one level. Use', 'Investigations', 'to <1000/mm³', 'of growth factors is allowed.', 'Platelet count', 'decreased', 'Delay chemotherapy by 1 week until', 'Cisplatin,', 'recovery to Grade 1. Consider reducing', '>Grade 2 (<75 X', '5FU', '109/L', 'dose by dose 20% for subsequent cycles', 'Bleeding >Grade 3', 'Delay chemotherapy by 1 week until', 'bleeding recovers to Grade 0-1', 'or requiring', 'Cisplatin ,', 'Investigations', 'Permanently discontinue chemotherapy,', '>2 platelet', '5FU', 'transfusions', 'or reduce dose by 20% or more for', 'subsequent cycles', 'Peripheral motor', 'Reduce dose by 20% and use reduced', 'Nervous system', 'neuropathy', 'Cisplatin', 'disorders', 'Grade 2', 'level for subsequent cycles', 'Peripheral motor', 'neuropathy', 'Cisplatin', 'Discontinue cisplatin', 'Grade 3 or higher', 'All other non-', '>Grade 3', 'Cisplatin,', 'Discontinue chemotherapy, or reduce dose', 'hematologic', '5FU', 'by 20% or more and use reduced dose for', 'subsequent cycles', 'Hold therapy till it recovers above', '50ml/min and restart at one dose level', 'GFR <50 ml/min,', 'lower or more if GFR goes down further.', 'Nephrotoxicity', 'first event', 'Cisplatin', 'If Patient GFR falls below 50ml/min even', 'with second dose reduction then omit', 'cisplatin and continue with RT alone.', ""a If a drug is held, omitted, discontinued or dose-reduced, it is the treating provider's discretion to apply the"", 'modification to one or both cytotoxic drugs, and the decision should depend on the nature and severity of the', 'particular adverse event and its likely causal relation to the agent.', 'b', 'For adverse effects >Grade 3 commonly associated with radiation such as radiation dermatitis, dry mouth,', 'mucositis, thick secretions/saliva, loss of taste, weight loss, loss of appetite dose modifications for', 'chemotherapy will be at the discretion of the treating provider.', '**', 'Use the following to describe actions in the Action column:', 'Protocol Version Date: 21JUN2018']"
36,page_37,"['MC1752', '37', 'Omit = The current dose(s) for the specified drug(s) during a cycle is skipped. The patient does', 'not make up the omitted dose(s) at a later time.', 'Hold/Delay = The current dose(s) of all drugs during a cycle is delayed. The patient does make', 'up the delayed dose(s) when the patient meets the protocol criteria to restart drugs.', 'Discontinue = The specified drug(s) are totally stopped.', 'NOTE: If the patient experiences a significant adverse event requiring a dose reduction at the start of the next', 'cycle, then the dose will remain lowered for that entire subsequent cycle. If that cycle is completed with no further', ""adverse events >Grade 2, then the dose may be increased, at the investigator's discretion, one level at a time, in"", 'the following cycles.', 'NOTE: Adverse events requiring a dose-reduction step for any or all drugs beyond the two dose-reduction steps', '(levels -1 - and -2) will be at the discretion of the treating provider, if the decision is made for the patient to be', 'kept on study. These dose reductions must be clearly recorded in reported clinical data. Patients can also continue', 'with RT alone without chemotherapy if the treating provider chooses to hold chemotherapy.', 'Treatment at reduced dosage will be administered once the adverse event has come down to grade 1 or less', '9.0', 'Ancillary Treatment/Supportive Care', '9.1', 'Full supportive care', 'Patients should receive full supportive care while on this study. This includes blood product', 'support, antibiotic treatment, and treatment of other newly diagnosed or concurrent medical', 'conditions. All blood products and concomitant medications such as antidiarrheals, analgesics,', 'and/or antiemetics received from the first day of study treatment administration until 30 days after', 'the final dose will be recorded in the medical records.', 'Suggested supportive care measures for the management of adverse events with potential', 'immunologic etiology are outlined below. Where appropriate, these guidelines include the use of', 'oral or intravenous treatment with corticosteroids as well as additional anti inflammatory agents', 'if symptoms do not improve with administration of corticosteroids. Note that several courses of', 'steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased.', 'For each disorder, attempts should be made to rule out other causes such as metastatic disease or', 'bacterial or viral infection, which might require additional supportive care. The treatment', 'guidelines are intended to be applied when the investigator determines the events to be related to', 'avelumab.', 'Note: if after the evaluation the event is determined not to be related, the investigator does not', 'need to follow the treatment guidance (as outlined below). Refer to Section 8.2 for dose', 'modification.', 'It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin', 'photography as part of evaluation of the event.', '9.2', 'Blood products and growth factors', 'Blood products and growth factors should be utilized as clinically warranted and following', 'institutional policies and recommendations. The use of growth factors should follow published', 'guidelines of the Journal of Clinical Oncology 2015;33(28):3199-3212.', '9.21', 'Neutropenia', 'Prophylactic use of colony-stimulating factors including Granulocyte Colony-Stimulating', 'Factor (G-CSF), pegylated G-CSF or Granulocyte Macrophage Colony-Stimulating', 'Factor GM-CSF is not allowed in this study. Therapeutic use of G-CSF is allowed in', 'patients with Grade 3-4 febrile neutropenia.', 'Protocol Version Date: 21JUN2018']"
37,page_38,"['MC1752', '38', '9.22', 'Anemia', 'Transfusions and/or erythropoietin may be utilized as clinically indicated for the', 'treatment of anemia, but should be clearly noted as concurrent medications.', '9.23', 'Thrombocytopenia', 'Transfusion of platelets may be used if clinically indicated. ITP should be ruled out', 'before initiation of platelet transfusion.', '9.3', 'Anti-infectives', 'Patients with a documented infectious complication should receive oral or IV antibiotics or other', 'anti-infective agents as considered appropriate by the treating Investigator for a given infectious', 'condition, according to standard institutional practice.', '9.4', 'Corticosteroids', 'Patients may continue on steroid inhalation therapy. Systemic corticosteroids are known', 'immunosuppressive agents that can mitigate the effects of avelumab. Steroids should be generally', 'reserved to treat side effects of avelumab. Steroids can be used as primary prevention of nausea', 'per institutional guidelines, but steroid doses should be reduced in subsequent cycles if', 'nausea/vomiting is absent or very mild (see Section 9.5).', '9.5', 'Antiemetics', 'Antiemetics may be used at the discretion of the attending physician. Nausea and vomiting should', 'be treated aggressively, and consideration should be given to the administration of prophylactic', 'antiemetic therapy according to standard institutional practice. Patients should be strongly', 'encouraged to maintain liberal oral fluid intake. Volume depletion should be corrected before', 'initiation of study drug. Study team strongly recommends use of dexamethasone to be restricted', 'to 4 mg once a week. We strongly recommend using long acting 5HT-3 inhibitors like', 'palonosetrone and Nk1 inhibitor like fosprepitant or olanzapine to avoid delayed nausea esp. with', 'cisplatin.', '9.6', 'Anti-diarrheals', 'Patients should be monitored for signs and symptoms of enterocolitis (such as diarrhea,', 'abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as', 'peritoneal signs and ileus). In symptomatic patients, infectious etiologies should be ruled out, and', 'if symptoms are persistent and/or severe, endoscopic evaluation should be considered. (See', 'Section 9.7 for management of treatment-related enterocolitis)', 'All patients who experience diarrhea should be advised to drink liberal quantities of clear fluids.', 'If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV', 'infusion.', 'NOTE: Loperamide/diphenoxylate/atropines should NOT be used for diarrhea symptoms unless:', '(1) it is believed that avelumab-related enterocolitis is unlikely to be present after detailed', 'evaluation by gastroenterology, including endoscopy; PLUS (2) approval is documented by a', 'gastroenterology specialist.', '9.7', 'Immunotherapy-related toxicities', 'Patients should be monitored for signs and symptoms of immunotherapy-related toxicities, which', 'include but are not limited to the following:', 'Pneumonitis', 'For Grade 2 events, treat with systemic corticosteroids (1.0 to 2.0 mg/kg/day prednisone', 'Protocol Version Date: 21JUN2018']"
38,page_39,"['MC1752', '39', 'or equivalent).', 'When symptoms improve to Grade 1 or less, steroid taper should be started and', 'continued over no less than 4 weeks.', 'For Grade 3-4 events, immediately treat with intravenous steroids (1.0 to 2.0 mg/kg/day', 'prednisone or equivalent). Administer additional anti-inflammatory measures, as needed.', 'Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid', 'administration.', 'Diarrhea/colitis', 'Patients should be carefully monitored for signs and symptoms of enterocolitis (such as', 'diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel', 'perforation (such as peritoneal signs and ileus).', 'All patients who experience diarrhea/colitis should be advised to drink liberal quantities', 'of clear fluids. If sufficient oral fluid intake is not feasible, fluid and electrolytes should', 'be substituted via IV infusion. For Grade 2 or higher diarrhea, consider GI consultation', 'and endoscopy to confirm or rule out colitis.', 'For Grade 2 diarrhea/colitis, administer oral corticosteroids and antidiarrheals.', 'For Grade 3 or 4 diarrhea/colitis, treat with intravenous steroids followed by high dose', 'oral steroids (1.0 to 2.0 mg/kg/day prednisone IV or equivalent). Add prophylactic', 'antibiotics for opportunistic infections.', 'When symptoms improve to Grade 1 or less, steroid taper should be started and', 'continued over no less than 4 weeks.', 'Type 1 Diabetes Mellitus (if new onset, including diabetic ketoacidosis [DKA]) or', '>Grade 3 Hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis', '(DKA)', 'For T1DM or Grade 3-4 Hyperglycemia:', 'Insulin replacement therapy is recommended for Type I diabetes mellitus and for Grade', '3-4 hyperglycemia associated with metabolic acidosis or ketonuria.', 'Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated', 'hemoglobin, and C-peptide.', 'Hypophysitis', 'For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or', 'less, steroid taper should be started and continued over no less than 4 weeks.', 'Replacement of appropriate hormones may be required as the steroid dose is tapered.', 'For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by oral', 'corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be', 'started and continued over no less than 4 weeks. Replacement of appropriate hormones', 'may be required as the steroid dose is tapered.', 'Hyperthyroidism or hypothyroidism', 'Thyroid disorders can occur at any time during treatment. Monitor patients for changes in', 'thyroid function (at the start of treatment, periodically during treatment, and as indicated', 'based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.', 'Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism):', 'In hyperthyroidism, non-selective beta-blockers (e.g. propranolol) are suggested as', 'initial therapy.', 'In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine', 'or', 'liothyroinine, is indicated per standard of care.', 'Grade 3-4 hyperthyroidism', 'Protocol Version Date: 21JUN2018']"
39,page_40,"['MC1752', '40', 'Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. When', 'symptoms improve to Grade 1 or less, steroid taper should be started and continued', 'over no less than 4 weeks. Replacement of appropriate hormones may be required as', 'the steroid dose is tapered.', 'Hepatic', 'For Grade 2 events, monitor liver function tests more frequently until returned to', 'baseline values (consider weekly).', 'Treat with IV or oral corticosteroids (1 to 2mg/kg/day prednisone or equivalent.)', 'Add prophylactic antibiotics for opportunistic infections', 'For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours.', 'When symptoms improve to Grade 1 or less, a steroid taper should be started and', 'continued over no less than 4 weeks.', 'Renal failure or nephritis', 'For Grade 2 events, treat with corticosteroids.', 'For Grade 3-4 events, treat with systemic corticosteroids.', 'When symptoms improve to Grade 1 or less, steroid taper should be started and', 'continued over no less than 4 weeks.', '9.8', 'Management of treatment related enterocolitis', 'In patients with severe enterocolitis, avelumab will be held and treatment with systemic', 'corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day of prednisone or equivalent.', 'When symptoms improve to Grade 1 or less, corticosteroid taper should be started and continued', 'over at least 1 month.', 'In patients with moderate enterocolitis, avelumab should be withheld and antidiarrheal treatment', 'should be started. If symptoms are persistent for more than one week, systemic corticosteroids', 'should be initiated (e.g., 0.5 mg/kg/day of prednisone or equivalent). When symptoms improve to', 'Grade 1 or less, corticosteroid taper should be started and continued over at least 1 month.', '9.9a', 'Concomitant Medications/Vaccinations (Allowed & Prohibited)', 'Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed', 'during the ongoing trial. If there is a clinical indication for any medication or vaccination', 'specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be', 'required. The final decision on any supportive therapy or vaccination rests with the investigator', ""and/or the patient's primary treating provider."", '9.91', 'Acceptable Concomitant Medications', ""All treatments that the investigator considers necessary for a subject's welfare may be"", 'administered at the discretion of the investigator in keeping with the community', 'standards of medical care. All concomitant medication will be recorded in the case report', 'forms (CRF) including all prescription, over-the-counter (OTC), herbal supplements, and', 'IV medications and fluids. If changes occur during the trial period, documentation of', 'drug dosage, frequency, route, and date may also be included on the CRF.', 'All concomitant medications received within 28 days before the first dose of trial', 'treatment and 30 days after the last dose of trial treatment should be recorded.', 'Concomitant medications administered 30 days after the last dose of trial treatment', 'should be recorded for SAEs and ECIs as defined in Section 10.', '9.92', 'Prohibited Concomitant Medications', 'Protocol Version Date: 21JUN2018']"
40,page_41,"['MC1752', '41', 'The following medications are not permitted during the screening and treatment phase', '(including retreatment for post-complete response relapse) of this trial:', 'Anti-neoplastic systemic cytotoxic chemotherapy or biological therapy outside the', 'clinical trial program', 'Immunotherapy not specified in this protocol', 'Chemotherapy not specified in this protocol', 'Investigational agents other than avelumab', 'Live vaccines within 30 days prior to the first dose of trial treatment and while', 'participating in the trial. Examples of live vaccines include, but are not limited to, the', 'following: measles, mumps, rubella, varicella/zoster, yellow fever, intranasal', 'influenza, rabies, BCG, and typhoid vaccine.', 'Systemic glucocorticoids for any purpose other than to modulate symptoms from an', 'event of clinical interest of suspected immunologic etiology. The use of physiologic', 'doses of corticosteroids may be approved after consultation with the principal', 'investigator.', 'NOTE: Use of steroids during chemoradiation for controlling chemotherapy-associated', 'is allowed. We recommend only using up to 4mg dexamethasone weekly.', 'Patients who, in the assessment by the investigator, require the use of any of the', 'aforementioned treatments for clinical management should be removed from the trial.', 'Patients may receive other medications that the investigator deems to be medically', 'necessary.', 'The Exclusion Criteria describes other medications which are prohibited in this trial.', 'There are no prohibited therapies during the Post-Treatment Follow-up Phase.', '9.9b', 'Contraception', 'Avelumab may have adverse effects on a fetus in utero. Furthermore, it is not known if avelumab', 'has transient adverse effects on the composition of sperm.', 'For this trial, male patients will be considered to be of non-reproductive potential if they have', 'azoospermia (whether due to having had a vasectomy or due to an underlying medical condition).', 'Female patients will be considered of non-reproductive potential if they are either:', '(1) postmenopausal (defined as at least 12 months with no menses without an alternative medical', 'cause; in women <45 years of age a high follicle stimulating hormone (FSH) level in the', 'postmenopausal range may be used to confirm a post-menopausal state in women not using', 'hormonal contraception or hormonal replacement therapy. In the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient.);', 'OR', '(2) have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral', 'tubal ligation/occlusion, at least 6 weeks prior to screening;', 'OR', '(3) has a congenital or acquired condition that prevents childbearing.', 'Female and male patients of reproductive potential must agree to avoid becoming pregnant or', 'impregnating a partner, respectively, while receiving study drug and for 120 days after the last', 'dose of study drug by complying with one of the following:', '(1) practice abstinence from heterosexual activity;', 'Protocol Version Date: 21JUN2018']"
41,page_42,"['MC1752', '42', 'OR', '(2) use (or have their partner use) acceptable contraception during heterosexual activity. Use in', 'Pregnancy', 'If a patient inadvertently becomes pregnant while on treatment with avelumab, the patient will', 'immediately be removed from the study. The site will contact the patient at least monthly and', ""document the patient's status until the pregnancy has been completed or terminated. The outcome"", 'of the pregnancy will be reported to Mayo Clinic and to EMD Serono without delay and within', '24 hours to Mayo Clinic and within 2 working days to EMD Serono if the outcome is a serious', 'adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or life-', 'threatening complication to the mother or newborn).', 'The study investigator will make every effort to obtain permission to follow the outcome of the', 'pregnancy and report the condition of the fetus or newborn. If a male subject impregnates his', 'female partner the study personnel at the site must be informed immediately and the pregnancy', 'reported to Mayo Clinic and to EMD Serono and followed as described above.', '9.9c', 'Use in Nursing Adults', 'Since many drugs are excreted in human milk, and because of the potential for serious adverse', 'reactions in the nursing infant, patients who are breast-feeding are not eligible for enrollment.', 'Specific additional information follows for individual agents used in this trial.', '9.9c1 Avelumab', 'It is unknown whether avelumab is excreted in human milk. It is recommend that nursing', 'mothers not to breast feed for at least one month after final dose.', '9.9c2 Chemotherapy', 'Cisplatin has been reported to be found in human milk; patients receiving cisplatin', 'injection should not breast-feed. It is not known if fluorouracil is present in breast milk.', 'Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer', 'recommends a decision be made to discontinue breastfeeding or to discontinue', 'fluorouracil, taking into account the importance of treatment to the mother.', 'It is not known if mitomycin is present in breast milk. Due to the potential for serious', 'adverse reactions in the breastfed infant, breastfeeding is not recommended by the', 'manufacturer.', 'Table 6. Pretreatment Medication', 'Agent', 'Dose', 'Route', 'Day', 'Prior to weekly cisplatin infusions', 'DXM', '4mg', 'IV or PO', 'Emend', '150 mg', 'IV', 'Prior to weekly Cisplatin', 'infusions', 'Palonosetron', '0.25mg', 'IV', 'Prior to weekly Cisplatin', 'infusions', 'Ondansetron', '8 mg', 'IV', 'C3D1 (Day 29) of Mitomycin +', '5-FU infusion', 'Prochlorperazine', '10 mg', 'PO', 'Prior to 5-FU infusion (~Day 50)', 'Protocol Version Date: 21JUN2018']"
42,page_43,"['MC1752', '43', '10.0', 'Adverse Event (AE) Monitoring and Reporting', 'The site principal investigator is responsible for reporting any/all serious adverse events to the sponsor as', 'described within the protocol, regardless of attribution to study agent or treatment procedure.', 'The sponsor/sponsor-investigator is responsible for notifying FDA and all participating investigators in a', 'written safety report of any of the following:', 'Any suspected adverse reaction that is both serious and unexpected.', 'Any findings from laboratory animal or in vitro testing that suggest a significant risk for human', 'subjects, including reports of mutagenicity, teratogenicity, or carcinogenicity.', 'Any findings from epidemiological studies, pooled analysis of multiple studies, or clinical', 'studies, whether or not conducted under an IND and whether or not conducted by the sponsor,', 'that suggest a significant risk in humans exposed to the drug', 'Any clinically important increase in the rate of a serious suspected adverse reaction over the rate', ""stated in the protocol or Investigator's Brochure (IB)."", 'Summary of SAE Reporting for this study', '(please read entire section for specific instructions):', 'WHO:', 'WHAT form:', 'WHERE to send:', 'Mayo Sites - attach to MCCC', 'Electronic SAE Reporting Form', 'Pregnancy Reporting', 'All sites', 'http://ctep.cancer.gov/protocolDevelopment/electronic a', 'Will automatically be sent', 'pplications/docs/PregnancyReportFormUpdated.pdf', 'to', 'Non Mayo sites - complete and', 'forward', 'to', 'Mayo Clinic Cancer Center SAE Reporting Form:', 'Will automatically be sent', 'Mayo Clinic', 'to', 'Sites', 'Mayo Clinic Cancer Center SAE Reporting', 'Form:', 'Will automatically be sent', 'Mayo Clinic', 'to', 'Sites', 'AND attach', 'MedWatch 3500A:', 'http://www.fda.gov/downloads/AboutFDA/ReportsMal', 'nualsForms/Forms/UCM048334.pdf', 'Protocol Version Date: 21JUN2018']"
43,page_44,"['MC1752', '44', 'Definitions', 'Adverse Event', 'Any untoward medical occurrence associated with the use of a drug in humans, whether', 'or not considered drug related.', 'Suspected Adverse Reaction', 'Any adverse event for which there is a reasonable possibility that the drug caused the', 'adverse event.', 'Expedited Reporting', 'Events reported to sponsor within 24 hours, 5 days or 10 days of study team becoming', 'aware of the event.', 'Routine Reporting', 'Events reported to sponsor via case report forms', 'Events of Interest', 'Events that would not typically be considered to meet the criteria for expedited reporting,', 'but that for a specific protocol are being reported via expedited means in order to', 'facilitate the review of safety data (may be requested by the FDA or the sponsor).', '10.1', 'Adverse Event Characteristics', 'CTCAE term (AE description) and grade: The descriptions and grading scales found in the', 'revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be', 'utilized for AE reporting. All appropriate treatment areas should have access to a copy of the', 'CTCAE version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the CTEP web', 'site: (http://ctep.cancer.gov/protocolDevelopment/electronic: applications/ctc.htm)', 'a.', 'Identify the grade and severity of the event using the CTCAE version 5.0.', 'b. Determine whether the event is expected or unexpected (see Section 10.2).', 'c.', 'Determine if the adverse event is related to the study intervention (agent, treatment or', 'procedure) (see Section 10.3).', 'd. Determine whether the event must be reported as an expedited report. If yes, determine the', 'timeframe/mechanism (see Section 10.4).', 'e.', 'Determine if other reporting is required (see Section 10.5).', 'f.', 'Note: All AEs reported via expedited mechanisms must also be reported via the routine data', 'reporting mechanisms defined by the protocol (see Sections 10.6 and 18.0).', 'NOTE: A severe AE is NOT the same as a serious AE, which is defined in Section 10.4.', '10.2', 'Expected vs. Unexpected Events', 'Expected events - are those described within the Section 15.0 of the protocol, the study specific', 'consent form, package insert (if applicable), and/or the investigator brochure, (if an investigator', 'brochure is not required, otherwise described in the general investigational plan).', 'Unexpected adverse events or suspected adverse reactions are those not listed in Section 15.0 of', 'the protocol, the study specific consent form, package insert (if applicable), or in the investigator', 'brochure (or are not listed at the specificity or severity that has been observed); if an investigator', 'brochure is not required or available, is not consistent with the risk information described in the', 'general investigational plan.', 'Unexpected also refers to adverse events or suspected adverse reactions that are mentioned in the', 'investigator brochure as occurring with a class of drugs but have not been observed with the drug', 'Protocol Version Date: 21JUN2018']"
44,page_45,"['MC1752', '45', 'under investigation.', 'An investigational agent/intervention might exacerbate the expected AEs associated with a commercial', 'agent. Therefore, if an expected AE (for the commercial agent) occurs with a higher degree of severity', 'or specificity, expedited reporting is required.', 'NOTE: *The consent form may contain study specific information at the discretion of the', 'Principal Investigator; it is possible that this information may NOT be included in the protocol or', 'the investigator brochure. Refer to protocol or IB for reporting needs.', '10.3', 'Attribution to agent(s) or procedure', 'When assessing whether an adverse event (AE) is related to a medical agent(s) medical or', 'procedure, the following attribution categories are utilized:', 'Definite - The AE is clearly related to the agent(s)/procedure.', 'Probable - The AE is likely related to the agent(s)/procedure.', 'Possible - The AE may be related to the agent(s)/procedure.', 'Unlikely - The AE is doubtfully related to the agent(s)/procedure.', 'Unrelated - The AE is clearly NOT related to the agent(s)/procedure.', '10.31 AEs Experienced Utilizing Investigational Agents and Commercial Agent(s) on', 'the SAME (Combination) Arm', 'NOTE: When a commercial agent(s) is (are) used on the same treatment arm as the', 'investigational agent/intervention (also, investigational drug, biologic, cellular product, or', 'other investigational therapy under an IND), the entire combination (arm) is then', 'considered an investigational intervention for reporting.', 'An AE that occurs on a combination study must be assessed in accordance with the', 'guidelines for investigational agents/interventions.', 'An AE that occurs prior to administration of the investigational agent/intervention must be', 'assessed as specified in the protocol. In general, only Grade 4 and 5 AEs that are unexpected', 'with at least possible attribution to the commercial agent require an expedited report, unless', 'hospitalization is required. Refer to Section 10.4 for specific AE reporting requirements or', 'exceptions.', 'An investigational agent/intervention might exacerbate the expected AEs associated with a', 'commercial agent. Therefore, if an expected AE (for the commercial agent) occurs with a', 'higher degree of severity or specificity, expedited reporting is required.', 'An increased incidence of an expected adverse event (AE) is based on the patients', 'treated for this study at their site. A list of known/expected AEs is reported in the', 'package insert or the literature, including AEs resulting from a drug overdose.', 'Commercial agent expedited reports must be submitted to the FDA via MedWatch 3500A', 'for Health Professionals (complete all three pages of the form).', 'http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048334.p', 'df', '10.32 EXPECTED Serious Adverse Events: Protocol Specific Exceptions to Expedited Reporting', 'For this protocol only, the following Adverse Events/Grades are expected to occur within this population and do', 'not require Expedited Reporting. These events must still be reported via Routine Reporting (see Section 10.6).*', '*Report any clinically important increase in the rate of a serious suspected adverse reaction (at your study', 'site) over that which is listed in the protocol or investigator brochure as an expedited event.', '*Report an expected event that is greater in severity or specificity than expected as an expedited event.', 'Protocol Version Date: 21JUN2018']"
45,page_46,"['MC1752', '46', 'System Organ Class', 'CTCAE Grade at which the event', '(SOC)', 'Adverse event/ Symptoms', 'will not be expeditedly reported', 'General disorders and', 'Fatigue', 'Grade 3', 'administration site', 'Malaise', 'Grade 3', 'conditions', 'Skin and subcutaneous', 'Rash', '<Grade 4', 'tissue disorders', 'Erythema', '<Grade3', 'Colitis', '<Grade 3', 'Gastrointestinal disorders', 'Nausea', '<Grade 3', 'Vomiting', '<Grade 3', 'Renal and urinary', 'Cystitis', 'Grade3', 'disorders', 'Injury, poisoning and', 'Radiation dermatitis', '<Grade 3', 'procedural complications', 'Blood and lymphatic', 'Anemia', '<Grade 4', 'system disorder', 'Respiratory, thoracic and', 'Pneumonitis', '<Grade 3', 'mediastinal disorders', '1', 'These exceptions only apply if the adverse event does not result in hospitalization. If the adverse event', 'results in hospitalization, then the standard expedited adverse events reporting requirements must be', 'followed.', 'Specific protocol exceptions to expedited reporting should be reported expeditiously by investigators', 'ONLY if they exceed the expected grade of the event.', 'The following hospitalizations are not considered to be SAEs because there is no ""adverse event"" (i.e.,', 'there is no untoward medical occurrence) associated with the hospitalization:', 'Hospitalizations for respite care', 'Planned hospitalizations required by the protocol', 'Hospitalization planned before informed consent (where the condition requiring the hospitalization has', 'not changed post study drug administration)', 'Hospitalization for elective procedures unrelated to the current disease and/or treatment on this trial', 'Hospitalization for administration of study drug or insertion of access for administration of study drug', 'Hospitalization for routine maintenance of a device (e.g., battery replacement) that was in place before', 'study entry', 'Hospitalization, or other serious outcomes for signs and symptoms of progression of the cancer.', '10.4', 'Expedited Reporting Requirements for IND/IDE Agents', '10.41', 'Phase 1 and Early Phase 2 Studies: Expedited Reporting Requirements for Adverse', 'Events that Occur on Studies under an IND/IDE within 30 Days of the Last', 'Administration of the Investigational Agent/Intervention 1,2', 'Protocol Version Date: 21JUN2018']"
46,page_47,"['MC1752', '47', 'FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)', 'NOTE: Investigators MUST immediately report to the sponsor ANY Serious Adverse Events, whether or not they are', 'considered related to the investigational agent(s)/intervention (21 CFR 312.64)', 'An adverse event is considered serious if it results in ANY of the following outcomes:', '1) Death', '2)', 'A life-threatening adverse event', '3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for 24 hours', '4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions', '5)', 'A congenital anomaly/birth defect.', '6)', 'Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be', 'considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require', 'medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A', 'and ICH E6).', 'ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the sponsor within the', 'timeframes detailed in the table below.', 'Grade 3-5', 'Hospitalization', 'Grade 1 and Grade 2 Timeframes', 'Timeframes', 'Resulting in', 'Hospitalization', '7 Calendar Days', '>24 hrs', '24-Hour 3 Calendar Days', 'Not resulting in', 'Hospitalization', 'Not required', '>24 hrs', 'Expedited AE reporting timelines are defined as:', '""24-Hour; 3 Calendar Days"" - The AE must initially be reported within 24 hours of learning of the AE, followed by a', 'complete expedited report within 3 calendar days of the initial 24-hour report.', '""7 Calendar Days"" - A complete expedited report on the AE must be submitted within 7 calendar days of learning of', 'the AE.', '1-Serious adverse events that occur more than 30 days after the last administration of investigational agent/intervention', 'and have an attribution of possible, probable, or definite require reporting as follows:', 'Expedited 24-hour notification followed by complete report within 3 calendar days for:', 'All Grade 3, 4, and Grade 5 AEs', 'Expedited 7 calendar day reports for:', 'Grade 2 AEs resulting in hospitalization or prolongation of hospitalization', '2', 'For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half-lives, rounded UP', 'to the nearest whole day, after the agent/intervention was last administered. Footnote ""1"" above applies after this', 'reporting period.', 'Effective Date: May 5, 2011', 'NOTE: Refer to Section 10.32 for exceptions to Expedited Reporting', '10.42 General reporting instructions', 'The Mayo IND Coordinator will assist the sponsor-investigator in the processing of expedited', 'adverse events and forwarding of suspected unexpected serious adverse reactions (SUSARS) to', 'the FDA and IRB.', 'Use Mayo Expedited Event Report', 'form', 'for investigational agents or commercial/investigational agents on the same', 'arm.', 'See section 10,8 for submission requirements to EMD Serono.', 'Protocol Version Date: 21JUN2018']"
47,page_48,"['MC1752', '48', '10.5', 'Other Required Reporting', '10.51 Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSOS)', 'Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSOS) in general,', 'include any incident, experience, or outcome that meets all of the following criteria:', '1. Unexpected (in terms of nature, severity, or frequency) given (a) the research', 'procedures that are described in the protocol-related documents, such as the IRB-', 'approved research protocol and informed consent document; and (b) the', 'characteristics of the subject population being studied;', '2.', 'Related or possibly related to participation in the research (in this guidance', 'document, possibly related means there is a reasonable possibility that the incident,', 'experience, or outcome may have been caused by the procedures involved in the', 'research); and', '3. Suggests that the research places subjects or others at a greater risk of harm', '(including physical, psychological, economic, or social harm) than was previously', 'known or recognized.', 'Some unanticipated problems involve social or economic harm instead of the physical or', 'psychological harm associated with adverse events. In other cases, unanticipated', 'problems place subjects or others at increased risk of harm, but no harm occurs.', 'Note: If there is no language in the protocol indicating that pregnancy is not considered', 'an adverse experience for this trial, and if the consent form does not indicate that subjects', 'should not get pregnant/impregnate others, then any pregnancy in a subject/patient or a', ""male patient's partner (spontaneously reported) which occurs during the study or within"", '120 days of completing the study should be reported as a UPIRTSO.', 'Mayo Clinic Cancer Center (MCCC) Institutions:', 'If the event meets the criteria for IRB submission as a Reportable Event/UPIRTSO,', 'provide the Reportable Event coversheet and appropriate documentation', 'to', 'The Mayo Regulatory Affairs Office will', 'review and process the submission to the Mayo Clinic IRB.', '10.52', 'Death', 'Note: A death on study requires both routine and expedited reporting regardless of', 'causality, unless as noted below. Attribution to treatment or other cause must be', 'provided.', 'Any death occurring within 30 days of the last dose, regardless of attribution to an', 'agent/intervention under an IND/IDE requires expedited reporting within 24-hours.', 'Any death occurring greater than 30 days with an attribution of possible, probable, or', 'definite to an agent/intervention under an IND/IDE requires expedited reporting within', '24-hours.', 'Reportable categories of Death', 'Death attributable to a CTCAE term.', 'Death Neonatal: A disorder characterized by cessation of life during the first 28', 'days of life.', 'Death NOS: A cessation of life that cannot be attributed to a CTCAE term', 'associated with Grade 5.', 'Protocol Version Date: 21JUN2018']"
48,page_49,"['MC1752', '49', 'Sudden death NOS: A sudden (defined as instant or within one hour of the onset of', 'symptoms) or an unobserved cessation of life that cannot be attributed to a', 'CTCAE term associated with Grade 5.', 'Death due to progressive disease should be reported as Grade 5 ""Neoplasms', 'benign, malignant and unspecified (including cysts and polyps) - Other', '(Progressive Disease)"" under the system organ class (SOC) of the same name.', 'Evidence that the death was a manifestation of underlying disease (e.g.,', 'radiological changes suggesting tumor growth or progression: clinical', 'deterioration associated with a disease process) should be submitted.', '10.53', 'Secondary Malignancy', 'A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g.,', 'treatment with investigational agent/intervention, radiation or chemotherapy). A', 'secondary malignancy is not considered a metastasis of the initial neoplasm.', 'All secondary malignancies that occur following treatment with an agent under an', 'IND/IDE will be reported. Three options are available to describe the event:', 'Leukemia secondary to oncology chemotherapy (e.g., Acute Myeloctyic Leukemia', '[AML])', 'Myelodysplastic syndrome (MDS)', 'Treatment-related secondary malignancy', 'Any malignancy possibly related to cancer treatment (including AML/MDS) should', 'also be reported via the routine reporting mechanisms outlined in each protocol.', '10.54 Second Malignancy', 'A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a', 'metastasis from the initial malignancy). Second malignancies require ONLY routine reporting', 'unless otherwise specified:', '10.55 Pregnancy, Fetal Death, and Death Neonatal', 'If a female subject (or female partner of a male subject) taking investigational product', 'becomes pregnant, the subject taking should notify the Investigator, and the pregnant female', 'should be advised to call her healthcare provider immediately. The patient should have', 'appropriate follow-up as deemed necessary by her treating provider. If the baby is born with a', 'birth defect or anomaly, a second expedited report is required.', 'Prior to obtaining private information about a pregnant woman and her infant, the investigator', ""must obtain consent from the pregnant woman and the newborn infant's parent or legal"", 'guardian before any data collection can occur. A consent form will need to be submitted to the', 'IRB for these subjects if a pregnancy occurs. If informed consent is not obtained, no', 'information may be collected.', 'In cases of fetal death, miscarriage or abortion, the mother is the patient. In cases where the', 'child/fetus experiences a serious adverse event other than fetal death, the child/fetus is the', 'patient.', 'NOTE: When submitting Mayo Expedited Adverse Event Report reports for ""Pregnancy"",', '""Pregnancy loss"", or ""Neonatal loss"", the potential risk of exposure of the fetus to the', 'investigational agent(s) or chemotherapy agent(s) should be documented in the ""Description of', 'Event"" section. Include any available medical documentation. Include this', 'form: http://ctep.cancer.gov/protocolDevelopment/electronic applications/docs/Pregnano', 'yReportFormUpdated.pdf', 'Protocol Version Date: 21JUN2018']"
49,page_50,"['MC1752', '50', '10.551 Pregnancy', 'Pregnancy should be reported in an expedited manner as Grade 3 ""Pregnancy,', 'puerperium and perinatal conditions - Other (pregnancy)"" under', 'the', 'Pregnancy, puerperium and perinatal conditions SOC. Pregnancy should be', 'followed until the outcome is known.', '10.552 Fetal Death', 'Fetal death is defined in CTCAE as ""A disorder characterized by death in utero;', 'failure of the product of conception to show evidence of respiration, heartbeat, or', 'definite movement of a voluntary muscle after expulsion from the uterus, without', 'possibility of resuscitation.""', 'Any fetal death should be reported expeditiously, as Grade 4 ""Pregnancy,', 'puerperium and perinatal conditions - Other (pregnancy loss)"" under the', 'Pregnancy, puerperium and perinatal conditions SOC.', '10.553 Death Neonatal', 'Neonatal death, defined in CTCAE as ""A disorder characterized by cessation of', 'life occurring during the first 28 days of life"" that is felt by the investigator to be', 'at least possibly due to the investigational agent/intervention, should be reported', 'expeditiously.', 'A neonatal death should be reported expeditiously as Grade 4 ""General', 'disorders and administration - Other (neonatal loss)"" under the General', 'disorders and administration SOC.', '10.6', 'Required Routine Reporting', '10.61', 'Baseline and Adverse Events Evaluations', 'Pretreatment symptoms/conditions to be graded at baseline and adverse events to be', 'graded at each evaluation.', 'Grading is per CTCAE v5.0 unless alternate grading is indicated in the table below:', 'Each', 'System Organ Class (SOC)', 'Adverse event/Symptoms', 'Baseline', 'evaluation', 'General disorders and', 'Pain', 'X', 'X', 'administration site', 'Fatigue', 'X', 'X', 'conditions', 'Injury, poisoning and', 'Dermatitis Radiation', 'X', 'X', 'procedural complications', 'Metabolism and nutrition', 'Anorexia', 'X', 'X', 'disorders', 'Musculoskeletal and', 'Bone pain', 'X', 'X', 'connective tissue disorders', 'Vascular disorders', 'Lymphedema', 'X', 'X', 'Respiratory, thoracic and', 'Pneumonitis', 'X', 'X', 'mediastinal disorders', 'Pulmonary fibrosis', 'X', 'X', 'Renal and urinary disorders', 'Hematuria', 'X', 'X', 'Protocol Version Date: 21JUN2018']"
50,page_51,"['MC1752', '51', 'Each', 'System Organ Class (SOC)', 'Adverse event/Symptoms', 'Baseline', 'evaluation', 'Urinary frequency', 'X', 'X', 'Urinary incontinence', 'X', 'X', 'Urinary retention', 'X', 'X', 'Urinary tract obstruction', 'X', 'X', 'Urinary tract pain', 'X', 'X', 'Urinary urgency', 'X', 'X', 'Number of stools', 'X', 'Diarrhea', 'X', 'Constipation', 'X', 'Fecal incontinence', 'X', 'X', 'Gastrointestinal disorders', 'Nausea', 'X', 'X', 'Proctitis', 'X', 'X', 'Rectal hemorrhage', 'X', 'X', 'Vomiting', 'X', 'X', '10.62', 'All other AEs', 'Submit via appropriate MCCC Case Report Forms (i.e., paper or electronic, as', 'applicable) the following AEs experienced by a patient and not specified in', 'Section 10.6:', '10.621 Grade 2 AEs deemed possibly, probably, or definitely related to the study', 'treatment or procedure.', '10.622 Grade 3 and 4 AEs regardless of attribution to the study treatment or', 'procedure.', '10.623 Grade 5 AEs (Deaths)', ""10.6231Any death within 30 days of the patient's last study treatment or"", 'procedure regardless of attribution to the study treatment or', 'procedure.', ""10.6232Any death more than 30 days after the patient's last study"", 'treatment or procedure that is felt to be at least possibly', 'treatment related must also be submitted as a Grade 5 AE, with a', 'CTCAE type and attribution assigned.', '10.7', 'Late Occurring Adverse Events', 'Refer to the instructions in the Forms Packet (or electronic data entry screens, as applicable)', 'regarding the submission of late occurring AEs following completion of the Active Monitoring', 'Phase (i.e., compliance with Test Schedule in Section 4.0).', '10.8', 'EMD Serono - Additional Event Reporting Instructions', 'The following reportable events must be submitted to EMD Serono within 24 hours (or', 'immediately for death or life-threatening events) using the applicable safety report form provided.', 'Serious Adverse Events', 'Exposure during Pregnancy or Breastfeeding (even if not associated with an adverse', 'event)', 'Protocol Version Date: 21JUN2018']"
51,page_52,"['MC1752', '52', 'Occupational exposure (even if not associated with an adverse event)', ""Potential drug-induced liver injury (Hy's Law cases): These events are considered"", 'important medical events and should be reported as SAEs.', 'Contact information for submission of reportable events to EMD Serono:', 'Fax:', 'OR', 'E-mail', 'Specifying:', 'PROTOCOL Number', 'SUBJECT Number', 'SITE Number/PI Name', 'SAE/ONSET DATE', '11.0', 'Treatment Evaluation', 'This study will not use RECIST criteria to evaluate response or progression. The patients enrolled will', 'have nonmeasurable disease on imaging and response will be evaluated with biopsy or cytology at 6, 9', 'and 12 months post therapy.', '11.1', 'Schedule of Evaluations:', 'For the purposes of this study, patients should be reevaluated every 12 weeks after registration for', 'the first year. The first 12 week evaluation will be a cross sectional imaging preferably same as', 'done at the time of registration with CT or MRI of chest abdomen and pelvis. Patient subsequent', '12 week assessment will include cross sectional imaging with office cystoscopy, cytology and', 'biopsy (for cause) Biopsy of the tumor bed at 6 months is mandatory. Patient will also have', 'routine blood work and translation and QOL assessments as described in the study table.', '11.2', 'Criteria for evaluation and endpoint analysis.', 'a.', 'Complete Response', 'Complete Response: Negative biopsy and negative urine cytology at 6 months from', 'registration after finishing of concurrent RT and immunotherapy. Imaging of abdomen and', 'pelvis confirming no systemic disease within 4 weeks of cystoscopy should be completed.', 'b. Progression', 'Progression: Progression in T stage, N stage or M stage both clinically or radiologically.', 'Histological confirmation of metastatic disease is at the discretion of the treating provider.', 'c. Recurrence', 'Recurrence: histologically proven first appearance of muscle invasive bladder cancer,', 'clinical evidence of metastatic disease, or treatment with radical cystectomy or radiation to', 'the bladder, or death due to any cause after they were confirmed remission at 6 month', 'evaluation', 'a.', 'Event : Histologically proven presence of muscle invasive bladder cancer, clinical', 'evidence of nodal or metastatic disease, radical cystectomy, death within 90 days of', 'protocol specified treatment.', 'Protocol Version Date: 21JUN2018']"
52,page_53,"['MC1752', '53', 'd. Performance Status', 'Performance Status: Patients will be graded according to the ECOG Performance Status', 'Scale. (Appendix I)', '12.0', 'Descriptive Factors:', '12.1', 'Histology: pure urothelial VS mixed histology', '12.2', 'Clinical T stage: T2 vs. T3 vs. T4', '12.3', 'Cohort: cohort 1 (5-FU + Mitomycin C) versus cohort 2 (Cisplatin) chemotherapy', ""NOTE: cohort selection is treating provider's choice"", '13.0', 'Treatment/Follow-up Decision at Evaluation of Patient', '13.1', 'Those patients who have experienced unacceptable toxicity may be eligible for retreatment at a', 'lower dose (see Section 8.0).', '13.2', 'Off Study/Safety Follow-up Visit:', 'Patients should be evaluated for any residual toxicities, per test schedule section 4.0. For patients', 'proceeding to cystectomy, this can coincide with traditional post-op visits. For patients who refuse to', 'return to clinic for an in-person visit, recording of patient reported toxicities by telephone is', 'acceptable.', '13.3', 'Those patients who refuse further treatment will go off treatment and be withdrawn from the', 'study.', '13.4', 'A patient is deemed ineligible if after registration, it is determined that at the time of registration,', 'the patient did not satisfy each and every eligibility criteria for study entry. The patient may', 'continue treatment off-protocol at the discretion of the treating provider as long as there are no', 'safety concerns, and the patient was properly registered. The patient will go or off study.', 'If the patient received treatment, all data up until the point of confirmation of ineligibility', 'must be submitted. Clinical follow-up will be required per Section 18.0 of the protocol.', 'If the patient never received treatment, on-study material must be submitted. The patient will', 'be taken off study.', '13.5', 'A patient is deemed a major violation, if protocol requirements regarding treatment in cycle 1 of', 'the initial therapy are severely violated that evaluability for primary end point is questionable. All', 'data up until the point of confirmation of a major violation must be submitted. The patient may', 'continue treatment off-protocol at the discretion of the treating provider as long as there are no', 'safety concerns, and the patient was properly registered.', '13.6', 'A patient is deemed a cancel if he/she is removed from the study for any reason before any study', 'treatment is given. On-study material and the End of Active Treatment/Cancel Notification Form', 'must be submitted. No further data submission is necessary.', '13.7', 'Criteria for Removal from Study', 'Patients will be removed from the study for any of the following reasons:', 'Completion of all study therapy and follow up.', 'Patient non-compliance or request to withdraw from all therapy and follow up. Patients who', 'withdraw from therapy only may continue to be followed for study specified follow up', 'secondary endpoints.', 'Protocol Version Date: 21JUN2018']"
53,page_54,"['MC1752', '54', 'Pregnancy.', ""Unacceptable toxicity that in the treating provider's discretion places the patient at risk for"", 'future significant harm.', 'Intercurrent illness that prevents continuation of therapy or follow up.', 'Protocol Version Date: 21JUN2018']"
54,page_55,"['MC1752', '55', '14.0', 'Body Fluid Biospecimens', '14.1', 'Collection and Processing', '14.11 Optional research specimen(s) collection per protocol IRB 16-005260 will be', 'done after consenting for 16-005260 and according to that protocol. All', 'collection time points and processing will be done per that protocol. Data from', 'IRB 16-005260 may be used for this study after IRB approval.', '15.0', 'Drug Information', '15.1', 'Avelumab (Bavencio)', '15.11', 'Background: Avelumab is a fully human IgG1 antibody directed against PD-L1.', 'Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its', 'receptors PD-1 and B7.1. This removes the suppressive effects of PD-L1 on anti-', 'tumor CD8+ T cells, resulting in the restoration of cytotoxic T cell response.', '15.12', 'Formulation: Avelumab is a sterile, clear, and colorless concentrate for solution', 'available in a concentration of 20 mg/mL. Each single-use vial contains 200', 'mg of avelumab as a preservative-free acetate-buffered solution (pH 5.2)', 'containing Mannitol, and Polysorbate 20 (Tween 20).', '15.13', 'Preparation and storage: Allow each vial to equilibrate to room temperature.', 'Avelumab drug product must be diluted in 250 mL of 0.9% saline solution', '(sodium chloride injection) supplied in an infusion bag; alternatively a 0.45%', 'saline solution can be used if needed. Use a disposable syringe equipped with a', 'needle of suitable size to remove a volume of sodium chloride solution to be', 'replaced by avelumab from the infusion bag and discard the removed solution.', 'Use a new disposable syringe equipped with a needle of suitable size to inject a', 'volume of avelumab drug product identical to the discarded volume of sodium', 'chloride solution into the infusion bag. Gently invert the mixture 10 times.', 'Infusion bags must not be shaken, in order to avoid foaming or excessive', 'shearing of the protein solution. The preparation must be carefully inspected as it', 'should result in a homogeneous looking clear solution, free of visible particles.', 'No other drugs should be added to the solution for infusion containing avelumab.', 'Avelumab drug product must be stored at 2°C to 8°C until use. If not used', 'immediately, the diluted drug product can be stored up to 8 hours at room', 'temperature or up to 24 hours at 2°C to 8°C. Avelumab drug product must not be', 'frozen.', '15.14 Administration: Avelumab is administered as a 1-hour IV infusion. Administer', 'the diluted solution through an intravenous line containing a sterile, non-', 'pyrogenic, low protein binding in-line filter (pore size of 0.2 micron).', '15.15 Pharmacokinetic information:', 'Absorption: Avelumab is administered intravenously and is 100%', 'bioavailable. Steady-state concentrations of avelumab are expected to be', 'Protocol Version Date: 21JUN2018']"
55,page_56,"['MC1752', '56', 'reached by the 3rd dosing cycle (10 mg/kg dose every 2 weeks), and the', 'accumulation ration is 1.25.', 'Distribution: The geometric mean volume of distribution at steady state for a', 'subject receiving 10 mg/kg was 4.72 L.', 'Metabolism: Avelumab is degraded by proteolytic catabolism. CYP450 does', 'not contribute to its metabolism.', 'Elimination: The primary elimination mechanism of avelumab is proteolytic', 'degradation. Based on population pharmacokinetic analyses in patients with solid', 'tumors, the total systemic clearance was 0.59 L/day. The terminal half-life was', '6.1 days in patients receiving 10 mg/kg every 2 weeks.', '15.16', 'Potential Drug Interactions: Avelumab is not expected to have drug-drug', 'interactions with other drugs because it is primarily metabolized through', 'catabolic pathways and is not expected to affect the expression of CYP450', 'enzymes.', '15.17 Known potential toxicities: Consult the package insert for the most current and', 'complete information.', 'Very Common @> 10%): Anemia, nausea, diarrhea, vomiting, abdominal pain,', 'fatigue, pyrexia, peripheral edema, infusion related reaction, weight decreased,', 'decreased appetite, back pain, arthralgia, cough, dyspnea', 'Common ( 1% - < 10%): Hypothyroidism, chills, pneumonitis, rash, pruritus,', 'rash maculopapular', 'Uncommon @> 0.1% - < 1%): Adrenal insufficiency, hyperthyroidism,', 'thyroiditis, autoimmune thyroiditis, adrenocortical insufficiency acute,', 'hypopituitarism, uveitis, colitis, autoimmune colitis, enterocolitis, autoimmune', 'hepatitis, acute hepatic failure, hepatic failure, hepatitis, drug hypersensitivity,', 'anaphylactic reaction, aspartate aminotransferase (AST) increased, alanine', 'aminotransferase (ALT) increased, blood creatine phosphokinase increased,', 'transaminases increased, diabetes mellitus, myositis, Guillian-Barré syndrome,', 'tubulointerstitial nephritis, rash pruritic, erythema, rash generalized, rash', 'erythematous, rash macular, rash papular, dermatitis exfoliative, erythema', 'multiforme, pemphigoid, pruritis generalized.', 'Adverse reactions with observed fatal outcome in the avelumab clinical', 'development programs included: immune-related pneumonitis, immune-related', 'hepatitis, and immune-related myocarditis.', '15.18 Drug procurement:', 'Investigational avelumab is provided free of charge to patients by EMD', 'Serono a subsidiary of Merk KGaA. Outdated or remaining drug is to', 'be destroyed on-site per procedures and local regulations in place at each', 'institution.', '15.19', 'Nursing Guidelines:', '15.191 Avelumab side effects vary greatly from those of traditional', 'chemotherapy and can vary in severity from mild to life threatening.', 'Protocol Version Date: 21JUN2018']"
56,page_57,"['MC1752', '57', 'Instruct patients to report any side effects to the study team immediately.', 'Side effects may be immediate or delayed up to months after', 'discontinuation of therapy. Most side effects are reversible with prompt', 'intervention of corticosteroids.', '15.192 Diarrhea can be seen however is less common than that seen', 'with anti-CTLA-4 agents. However it can be severe, leading to colonic', 'perforation. Instruct patients to report ANY increase in the number of', 'stools and/or change in baseline, blood in the stool, abdominal pain to the', 'study team immediately.', '15.193 Rash/pruirits/dermatitis is seen. Rarely Steven Johnson', 'Syndrome has been seen and can be life threatening. Patients should', 'report any rash to the study team. Treat per section 9.0 and monitor for', 'effectiveness.', ""15.194 Monitor LFT's closely as elevations in these levels could"", 'indicate early onset autoimmune hepatitis. Patients should also be', 'instructed to report any jaundice, or right upper quadrant pain to the', 'study team immediately.', '15.195 Pneumonitis can be seen and may be mild (only seen on', 'imaging) to severe. Patients should be instructed to report any SOB,', 'dyspnea, cough, chest pain, etc. to the study team immediately. Patients', 'reporting these symptoms should have a pulse ox checked and consider', 'immediate imaging per the treating MD.', '15.196 Endocrinopathies (including hypopituitarism, hypothyroidism,', 'hypophysistis, and adrenal insufficiency) are seen with this agent.', 'Patients may present only with the vague sense of fatigue and ""not', 'feeling well"" Additional symptoms may be that of nausea, sweating and', 'decreased activity tolerance. Instruct patients to report these signs or', 'symptoms immediately and obtain appropriate labs as ordered by MD.', '15.197 Patients who are started on steroid therapy for any side effects of', 'avelumab toxicity should be instructed to take the steroids as ordered,', 'and not to discontinue abruptly as symptoms may return and be severe.', 'Patients may be on steroid therapy for weeks. Instruct patients to report', 'any increase or change in side effects with any dosage decrease as', 'patients may need a slower taper.', '15.198 Fatigue is common and may or may not be associated with', ""immune related side effects. Assess patient's fatigue level prior to each"", 'cycle of therapy and report any changes to the study team.', '15.199 Other rare side effects include Guillian-Barre syndrome,', 'nephritis, myocarditis, infusion reaction, and cytopenias. Instruct patients', 'to report and side effects to the study team immediately.', 'Protocol Version Date: 21JUN2018']"
57,page_58,"['MC1752', '58', '15.2', 'Fluorouracil (Adrucil, Efudex, [5FU])', '15.21', 'Background: Antineoplastic Agent, Antimetabolite (Pyrimidine Analog).', 'Fluorouracil is a fluorinated Pyrimidine Antimetabolite that inhibits thymidylate', 'synthetase, blocking the methylation of deoxyuridylic acid to thymidylic acid,', 'interfering with DNA, and to a lesser degree, RNA synthesis. Fluorouracil', 'appears to be phase specific for the G1 and S phases of the cell cycle.', '15.22', 'Formulation: Commercially available for injection 50 mg/mL (10 mL, 20 mL,', '50 mL, and 100 mL).', '15.23', 'Preparation, storage, and stability: Store intact vials at room', 'temperature and protect from light. A slight discoloration may occur with', 'storage but usually does not denote decomposition. Dilute in 50 - 1000', 'mL of 0.9% NaCl or D5W. If exposed to cold, a precipitate may form;', 'gentle heating to 60°C will dissolve the precipitate without impairing the', 'potency. Solutions in 50 - 1000 mL 0.9% NaCl or D5W or undiluted', 'solutions in syringes are stable for 72 hours at room temperature.', 'Fluorouracil should not be coadministered with either diazepam,', 'doxorubicin, daunorubicin, idarubicin, cisplatin, or cytarabine. However,', 'fluorouracil and leucovorin are compatible for 14 days at room', 'temperature. Fluorouracil is compatible with vincristine, methotrexate, and', 'cyclophosphamide.', '15.24', 'Administration: Fluorouracil may be given IV push, IV infusion.', 'Refer to section 7.0 (treatment) administration instructions specific to the', 'protocol.', '15.25', 'Pharmacokinetic information:', 'Distribution: Vd ~ 22% of total body water; penetrates extracellular', 'fluid, CSF, and third space fluids (e.g., pleural effusions and ascitic fluid)', 'Metabolism: Hepatic (90%); via a dehydrogenase enzyme; Fluorouracil', 'must be metabolized to be active.', 'Half-life elimination: Biphasic: Initial: 6-20 minutes; two metabolites,', 'FdUMP and FUTP, have prolonged half-lives depending on the type of', 'tissue.', 'Excretion: Lung (large amounts as CO2); urine (5% as unchanged drug)', 'in 6 hours.', '15.26', 'Potential Drug Interactions: Fluorouracil may increase effects of', 'warfarin. Avoid ethanol (due to GI irritation). Avoid black cohosh.', '15.27', 'Known potential adverse events: Consult the package insert for the most', 'current and complete information.', 'Common known potential toxicities, > 10%:', 'Dermatologic: Dermatitis, pruritic maculopapular rash, alopecia.', 'Gastrointestinal (route and schedule dependent): Heartburn, nausea,', 'vomiting, anorexia, stomatitis, esophagitis, anorexia, diarrhea. GI toxicity', '(anorexia, nausea, and vomiting) is generally more severe with', 'continuous-infusion schedules.', 'Protocol Version Date: 21JUN2018']"
58,page_59,"['MC1752', '59', 'Emetic potential: <1000 mg: Moderately low (10% to 30%) > 1000 mg:', 'Moderate (30% to 60%)', 'Hematologic: Leukopenia; Myelosuppressive (tends to be more', 'pronounced in patients receiving bolus dosing of FU). Decreased white', 'blood cell count with increased risk of infection; decreased platelet count', 'with increased risk of bleeding.', 'Local: Irritant chemotherapy.', 'Less common known potential toxicities, 1% - 10%:', 'Dermatologic: Dry skin', 'Gastrointestinal: GI ulceration', 'Rare known potential toxicities, <1% (Limited to important or life-', 'threatening):', 'Cardiac enzyme abnormalities, chest pain, coagulopathy, dyspnea, ECG', 'changes similar to ischemic changes, hepatotoxicity; hyperpigmentation of', 'nail beds, face, hands, and veins used in infusion; hypotension, palmar-', 'plantar syndrome (hand-foot syndrome), photosensitization. Cerebellar', 'ataxia, headache, somnolence, ataxia are seen primarily in intracarotid', 'arterial infusions for head and neck tumors.', '15.28', 'Drug procurement: Commercial supplies. Pharmacies or clinics shall', 'obtain supplies from normal commercial supply chain or wholesaler.', '15.29', 'Nursing Guidelines:', '15.291 Monitor complete blood count and platelet count. Instruct patient to', 'report signs and symptoms of infection, unusual bruising or bleeding to', 'the physician.', '15. 292 Administer antiemetics as indicated.', '15. 293 Diarrhea may be dose-limiting; encourage fluids and treat', 'symptomatically.', '15. 294 Assess for stomatitis; oral care measures as indicated. May try vitamin E', 'oil dabbed on sore, six times daily. Cryotherapy recommended with IV', 'push administration.', '15. . 295 Monitor for neurologic symptoms (headache, ataxia).', '15. 296 Inform patient of potential alopecia.', '15. 297 Those patients on continuous infusion may need instruction regarding', 'central intravenous catheters and portable intravenous or IA infusion', 'devices.', '15.298 5FU-induced conjunctivitis is a common problem. Advise patient to', 'report any eye soreness or redness to the healthcare team.', '15.299 Photosensitivity may occur. Instruct patients to wear sun block when', 'outdoors.', 'Protocol Version Date: 21JUN2018']"
59,page_60,"['MC1752', '60', '15.3', 'Mitomycin (Mutamycin®):', '15.31', 'Background: Mitomycin is an antitumor antibiotic that alkylates DNA to', 'produce DNA cross-linking (primarily with guanine and cytosine pairs) and', 'inhibits DNA and RNA synthesis. Mitomycin is not cell cycle specific but has', 'its maximum effect against cells in the late G and early S phases.', '15.32', 'Formulation: Commercially available for injection as:', 'Injection, solution reconstituted in 5 mg, 20 mg, and 40 mg vials.', '15.33 Preparation and storage: Store intact, unreconstituted mitomycin at controlled', 'room temperature and is stable for the lot life indicated on the package. Avoid', 'excessive heat over 40 °C. Reconstituted mitomycin with Sterile Water for Inject', 'to a concentration of 0.5 mg/mL is stable for 14 days refrigerated or 7 days at', 'room temperature. Protect reconstituted solution from light. Diluted mitomycin', 'in various IV fluids at room temperature, a concentration of 20 to 40', 'micrograms/mL is stable as follows: in 5% Dextrose Injection - stable 3 hours,', 'in 0.9% Sodium Chloride Injection - stable 12 hours, and in Sodium Lactate', 'Injection - stable 24 hours. Administer IV push/bolus or via IV piggyback.', 'Consider using a central venous catheter as mitomycin is a vesicant.', '15.34 Administration: Administer by slow IV push/bolus via a freely-running saline', 'infusion.', '15.35', 'Pharmacokinetic information:', 'Metabolism: Primarily hepatic', 'Half-life elimination: 17 minutes (30 mg dose)', 'Excretion: Feces primarily; urine', '15.36', 'Potential Drug Interactions:', 'Metabolism/Transport Effects: Substrate P-glycoprotein', 'Increased Effect/Toxicity: The levels/effects of mitomycin may be', 'increased by P-glycoprotein/ABCBI inhibitors, vinca alkaloids,', 'denosumab, dipyrone, palifermin, pimecrolimus, ronalazine, roflumilast,', 'trastuzumab.', 'Decreased Effect: The levels/effects of mitomycin may be decreased by', 'Echinacea, Lumacaftor, P-glycoprotein/ABCBI inducers.', '15.37 Known potential toxicities: Consult the package insert for the most current and', 'complete information. US Boxed Warnings include: Bone marrow suppression,', 'hepatotoxicity, carcinogenic and teratogenic.', 'Common known potential toxicities, > 10%:', 'Gastrointestinal: Nausea, vomiting, anorexia', 'Hematologic & oncologic: Bone marrow depression, hemolytic-uremic', 'syndrome (HUS), thrombotic thrombocytopenic purpura (TTP)', 'Miscellaneous: Fever', 'Less common known potential toxicities, 1% - 10%:', 'Dermatologic: Alopecia', 'Gastrointestinal: Mucous membrane disease, stomatitis', 'Protocol Version Date: 21JUN2018']"
60,page_61,"['MC1752', '61', 'Renal: Increased serum creatinine', 'Rare known potential toxicities, <1% (Limited to important or life-', 'threatening):', 'Adult respiratory distress syndrome (ARDS), bladder spasm (intravesical', 'administration), cardiac failure, dyspnea, extravasation reactions, fibrosis', '(bladder; intravesical administration), hepatic sinusoidal obstruction', 'syndrome (formerly known as hepatic veno-occlusive disease), interstitial', 'fibrosis, malaise, nonproductive cough, pulmonary infiltrates, renal failure', '(irreversible), skin rash, weakness', '15.38', 'Drug procurement: Commercial supplies. Pharmacies or clinics shall obtain', 'supplies from normal commercial supply chain or wholesaler.', '15.39', 'Nursing Guidelines:', '15.391 Administer antiemetics and antidiarrheals as needed.', '15.392 Monitor CBC and platelet count: Thrombocytopenia may be cumulative', 'and dose-limiting. Instruct patient to report any signs or symptoms of', 'infection, unusual bruising or bleeding to the health care team.', '15.393 Premedicate with antiemetics and assess for their effectiveness.', '15. 394 Monitor for interstitial pneumonitis and pulmonary fibrosis which may', 'respond to corticosteroid therapy.', '15. 395 Fatigue is common. Educate patient to incorporate rest periods in daily', 'routine.', '15. 396 Monitor for signs of hemolytic uremic syndrome. Characterized by rapid', 'fall in hemoglobin, renal failure (rise in creatinine), severe', 'thrombocytopenia, with progression to pulmonary edema and', 'hypotension. Assess creatinine before administration and hold dose and', 'inform MD if crt. >1.7 mg/dl.', '15.397 Mitomycin is a potent vesicant - avoid extravasation. Ensure patency of', 'IV before and throughout administration. If extravasation occurs stop', 'infusion and refer to your institutions treatment policy. Closely monitor', 'skin for signs of tissue necrosis, erythema, and tissue sloughing.', '15.398 Interstitial pneumonitis occurs rarely, but can be quite severe and lead to', 'ARDS. Assess baseline pulmonary status at initiation of treatment and', 'before subsequent cycles. Instruct patient to report any non-productive', 'cough, dyspnea, hemoptysis, or chest pain.', '15.4', 'Cisplatin (CDDP)', '15.41', 'Background: Cisplatin inhibits DNA synthesis by the formation of DNA cross-', 'links; denatures the double helix; covalently binds to DNA bases and disrupts', 'DNA function; may also bind to proteins. Cisplatin can also bind two adjacent', 'Protocol Version Date: 21JUN2018']"
61,page_62,"['MC1752', '62', 'guanines on the same strand of DNA producing intrastrand cross-linking and', 'breakage.', '15.42', 'Formulation: Commercially available for injection as:', 'Solution [preservative free]: 1 mg/mL (50 mL, 100 mL, 200 mL)', '15.43 Preparation, storage, and stability: Refer to package insert for complete', 'preparation and dispensing instructions. Store intact vials at room temperature', 'and protect from light. Do not refrigerate solution, a precipitate may form.', 'Further dilution stability is dependent on the chloride ion concentration and', 'should be mixed in solutions of sodium chloride concentrations at least 0.3%', 'NaCl. Further dilutions in 0.9% NaCl, D5/0.45% NaCl, or D5/0.9% NaCl to', 'a', 'concentration of 0.05-2 mg/mL are stable for 72 hours at 4°C to 25°C. The', 'infusion solution should have a final sodium chloride concentration equal to or', 'greater than 0.2% NaCl.', '15.44 Administration: Refer to the treatment section for specific administration', 'instructions. When administered as sequential infusions, observational studies', 'indicate a potential for increased toxicity when platinum derivatives (carboplatin,', 'cisplatin) are administered before taxane derivatives (docetaxel, paclitaxel).', 'Pretreatment hydration with 1-2 L of fluid is recommended prior to cisplatin', 'administration; adequate hydration and urinary output (> 100 mL/hour) should be', 'maintained for 24 hours after administration. Hydration may be accomplished by', 'adding the appropriate dose of cisplatin to 750 mL 0.5 D5/0.45% NaCl with 25', 'grams of Mannitol (approximating 1000 mL final volume) and infused over', '2', 'hours. The IV rate of administration has varied from a 15- to 120-minute', 'infusion, 1 mg/minute infusion, 6- to 8-hour infusion, 24-hour infusion, or per', 'protocol; maximum rate of infusion of 1 mg/minute in patients with CHF.', '15.45', 'Pharmacokinetic information:', 'Distribution: Rapidly into tissue; high concentrations in kidneys, liver,', 'ovaries, uterus, and lungs', 'Protein binding: >90%', 'Metabolism: Nonenzymatic; inactivated (in both cell and bloodstream) by', 'sulfhydryl groups; covalently binds to glutathione and thiosulfate', 'Half-life elimination: Initial: 20-30 minutes; Beta: 60 minutes; Terminal:', '~ -24 hours; Secondary half-life: 44-73 hours', 'Excretion: Urine (>90%); feces (10%)', '15.46', 'Potential Drug Interactions:', 'Increased Effect/Toxicity: Delayed bleomycin elimination with', 'decreased Glomerular filtration rate. When administered as sequential', 'infusions, observational studies indicate a potential for increased toxicity', 'when platinum derivatives (carboplatin, cisplatin) are administered before', 'taxane derivatives (docetaxel, paclitaxel).', 'Decreased Effect: Sodium thiosulfate and amifostine theoretically', 'inactivate drug systemically; have been used clinically to reduce systemic', 'toxicity with administration of cisplatin.', 'Protocol Version Date: 21JUN2018']"
62,page_63,"['MC1752', '63', 'Herb/Nutraceutical Interactions: Avoid black cohosh, dong quai in', 'estrogen-dependent tumors.', '15.47 Known potential adverse events: Consult the package insert for the most', 'current and complete information.', 'Common known potential toxicities, > 10%:', 'Central nervous system: Neurotoxicity: Peripheral neuropathy is dose-', 'and duration-dependent', 'Dermatologic: Mild alopecia', 'Gastrointestinal: Nausea and vomiting', 'Hematologic: Anemia, leukopenia (nadir day 18-23, recovery by day 39,', 'dose related), thrombocytopenia (nadir day 18-23, recovery by day 39,', 'dose related)', 'Hepatic: Liver enzymes increased', 'Renal: Nephrotoxicity (acute renal failure and chronic renal', 'insufficiency)', 'Otic: Ototoxicity, manifested as high frequency hearing loss; ototoxicity', 'is especially pronounced in children', 'Less common known potential toxicities, 1% - 10%:', 'Local: Tissue irritation', 'Rare known potential toxicities, <1% (Limited to important or life-', 'threatening):', 'Alopecia, ageusia, anaphylaxis, aortic thrombosis, autonomic neuropathy,', 'bradycardia, cardiac arrhythmia, cardiac failure, cerebrovascular accident,', 'extravasation, hemolytic anemia (acute), hemolytic-uremic syndrome,', 'hiccups, hypercholesterolemia, hyperuricemia, hypocalcemia,', 'hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia,', 'increased serum amylase, leukoencephalopathy, myocardial infarction,', 'neutropenic enterocolitis, optic neuritis, pancreatitis, papilledema,', 'peripheral ischemia (acute), phlebitis, SIADH, tachycardia, thrombotic', 'thrombocytopenic purpura', '15.48', 'Drug procurement: Commercial supplies. Pharmacies or clinics shall obtain', 'supplies from normal commercial supply chain or wholesaler.', '15.49', 'Nursing Guidelines:', '15.491 May react with aluminum IV set, forming a black precipitate and losing', 'its potency.', '15. 492 Assess laboratory values prior to drug administration, especially CBC,', 'platelets, creatinine.', '15. 493 Patient should be hydrated before administration. Stress post infusion', 'hydration maintenance to reduce risk of nephrotoxicity.', '15. 494 Administer aggressive antiemetic therapy pre- and post-treatment.', 'Protocol Version Date: 21JUN2018']"
63,page_64,"['MC1752', '64', '15.495 Monitor for signs of neurotoxicity and ototoxicity. Instruct patient to', 'report any numbness, burning, or tingling in hands and feet to health care team.', 'Also instruct patient to report any changes in hearing or ringing in the ears to', 'health care team.', '15.496 Monitor magnesium and potassium levels, and for signs and symptoms of', 'hypomagnesemia and hypokalemia, supplements may be needed.', '15.497 Instruct patient about alopecia.', '15.498 Use cautiously with loop diuretics as these may increase the risk of', 'ototoxicity.', '15.499aMonitor for signs and symptoms of allergic reactions. Treat according', 'to', ""your institution's protocol."", '15.499bMonitor renal function tests.', '16.0', 'Statistical Considerations and Methodology', '16.1', 'Overview: This protocol will assess the efficacy and safety of concurrent chemotherapy', 'radiation treatment combined with avelumab in patients with muscle invasive bladder', 'cancer using a two-stage Simon optimum design. A safety run-in with 6 patients', '(described in Section 7.0) will be conducted prior to the expansion portion.', 'A safety analysis will be conducted after 6 patients have been enrolled and have been', 'treated for a minimum of three cycles. Patients will be treated for the first two cycles', 'with avelumab only. Chemoradiation will begin at cycle 3 (Day 29) This will be', 'performed to determine whether or not the proposed combination chemotherapy regimen', '+ radiation therapy with avelumab is a safe regimen. ACCRUAL WILL BE', 'TEMPORARILY HALTED between the safety run-in and expansion portion in order to', 'evaluate the concurrent radiation therapy adverse event. This data will be reviewed by the', 'Study Chair and Study Statistician. The adverse event stopping rule in Section 16.42 will', 'be in effect for patients in the initial safety run-in portion as well as patients in the', 'expansion portion (efficacy portion) of this study. If this regimen at the proposed dosages', 'is deemed safe, these 6 patients will be considered the first 6 patients in this study.', 'Adverse events will continue to be monitored for all subsequent patients per the adverse', 'event stopping rule described in section 16.42.', '16.11 Primary Endpoint: The primary endpoint will be complete response (CR) at 6 months from', 'registration. This study will use the response criteria as described in section 11.0 to evaluate', 'response or progression. The patients enrolled will have nonmeasurable disease on imaging', 'and response will be evaluated with biopsy or cytology at 6 months post-registration. All', 'patients meeting the eligibility criteria who have signed a consent form, have begun treatment,', 'and have not been deemed a major treatment violation during the first cycle of treatment will', 'be evaluable for response.', 'Protocol Version Date: 21JUN2018']"
64,page_65,"['MC1752', '65', '16.12 Safety run-in portion: The safety run-in portion will consist of the first 6 patients enrolled', 'on the study. For a subject to be considered evaluable for dose-limiting toxicity (DLT) the', 'subject must have received at least two doses of avelumab for cycles 1-2 and chemoradiation', 'for cycle 3 (Day 29). If a subject withdraws from the study within the first 3 cycles of', 'treatment for reasons other than adverse events, the subject will be replaced; and only DLTs', 'occurring in Cycles 1-3 will be used for establishing safety during the run-in portion.', 'However, all adverse event data will be summarized in the final analysis. These 6 patients', 'will be included in the efficacy analysis. Safety for all patients (including the patients in the', 'run-in portion) will continue to be monitored via the Adverse Event Stopping Rule. Dose', 'limiting toxicity during cycle 3 (Day 29; in either portion) will be defined as described in', 'section 7.0', '16.2 Statistical Design', '16.21 Decision Rule: The largest success proportion (CR at 6 months post-registration) where the', 'proposed treatment regimen would be considered ineffective in this population is 65%, and', 'the smallest success proportion that would warrant subsequent studies with the proposed', 'regimen in this patient population is 85%. The following two-stage design based on', 'properties of the binomial distribution uses 27 patients to test the null hypothesis that the', 'true success proportion in a given patient population is at most 65%.', '16.211 Stage I: Enter 12 patients into the study. If 8 or fewer successes are observed in the first 12', 'evaluable patients, the study will conclude or the investigators will discuss with the, IRB, or', 'DSMB to determine if further investigation is warranted. Otherwise, if 9 or more successes', 'are observed in the first 12 evaluable patients, we will proceed to Stage 2. Accrual will', 'continue between Stage 1 and Stage 2 while patients become evaluable for the primary', 'endpoint.', '16.212 Stage 2: Enter an additional 15 patients into the study. If £20 or fewer successes are', 'observed in the first 27 evaluable patients, we may consider this regimen ineffective in this', ""patient population. If '21 or more successes are observed in the first 27 evaluable patients,"", 'we may recommend further testing of this regimen in subsequent studies in this population.', '16.213 Over Accrual: If more than the target number of patients are accrued, the additional patients', 'will not be used to evaluate the stopping rule or used in any decision making process.', '16.22 Sample Size: The two-stage study design to be utilized is fully described in Section 16.21. A', 'minimum of 27 evaluable patients are to be accrued onto this study unless undue adverse', 'events are encountered. We anticipate accruing an additional 3 patients to account for', 'ineligibility, cancellation, major treatment violation, or other reasons. Thus, a maximum of', '30 patients will be accrued onto this study in order to have 27 evaluable patients available', 'for the statistical design described in Section 16.21. There is no pre-specified maximum', 'accrual for the two chemotherapy cohorts.', '16.23 Accrual Time and Study Duration: The anticipated accrual rate is approximately 1-2 patients', 'per month, based on physician estimate. Therefore, the accrual period for this phase II study', 'Protocol Version Date: 21JUN2018']"
65,page_66,"['MC1752', '66', 'is expected to be 20 months. The final analysis can begin approximately 26 months after the', 'trial begins, i.e., as soon as the last patient has completed the 6 months post-registration', 'clinical follow-up visit.', '16.24 Power and Significance Level: Assuming that the number of successes is binomially', 'distributed, the significance level is <0.10 and the probability of declaring that this regimen', 'warrants further studies (i.e., statistical power) under various success proportions can be', 'tabulated as a function of the true success proportion as shown in the following table.', 'If the true success proportion is', '0.65', '0.70', '0.75', '0.80', '0.85', 'Then the probability of stopping', '0.65', '0.51', '0.35', '0.21', '0.09', 'accrual after Stage I is', 'And the probability of declaring that', '0.10', '0.22', '0.42', '0.65', '0.85', 'the regimen warrants further studies', 'is', '16.25 Other Considerations: Adverse events, quality/duration of response, and patterns of treatment', 'failure observed in this study, as well as scientific discoveries or changes in standard care', 'will be taken into account in any decision to terminate the study.', '16.3 Analysis Plan: The analysis for this trial will commence at planned time points and at the time', 'the patients have become evaluable for the primary endpoint. Such a decision will be made by', 'the Statistician and Study Chair, in accordance with Mayo Clinic Cancer Center (MCCC)', 'Standard Operating Procedures, availability of data for secondary endpoints (e.g., laboratory', 'correlates), and the level of data maturity.', '16.31 Primary Endpoint', '16.311 Definition: The primary endpoint of this trial is the proportion of patients who', 'achieve a complete response (CR) at 6 months post-registration as defined in', 'Section 16.11.', '16.312 Estimation: The proportion of successes will be estimated by the number of', 'successes divided by the total number of evaluable patients. Confidence intervals for', 'the true success proportion will be calculated using the properties of the binomial', 'distribution.', '16.313 Over Accrual: If more than the target number of patients are accrued, the additional', 'patients will not be used to evaluate the stopping rule or used in any decision', 'making processes; however, they will be included in final point estimates and', 'confidence intervals.', '16.32 Definitions and Analyses of Secondary Endpoints', 'Protocol Version Date: 21JUN2018']"
66,page_67,"['MC1752', '67', '16.321 Adverse Events: All eligible patients that have initiated treatment will be considered', 'evaluable for assessing adverse event rate(s). The maximum grade for each type of', 'adverse event will be recorded for each patient, and frequency tables will be', 'reviewed to determine patterns. Additionally, the relationship of the adverse event(s)', 'to the study treatment will be taken into consideration.', '16.322 Analysis of Patient-Reported Outcomes (EORTC QLQ-30, EORTCQOL-BLM30)', ':', 'Quality of life will be assessed at screening, at end of avelumab treatment, and EOS', '(12 month after registration). QOL will be measured using the EORTO QLQ-C30, a', '30-item patient-reported questionnaire about patient ability to function, symptoms', 'related to the cancer and its treatment, overall health and quality of life, and', 'perceived financial impact of the cancer and its treatment. 28 of the 30 items are', 'measured on a 1-4 scale (1=not at all; 4=very much) with the remaining two items', '(overall health and overall quality of life) scored on a 1-7 numeric analogue scale', '(1=very poor; 7=excellent). The recall period for the EORTC QLQ-C30 is one week.', 'The EORTC QLQ-C30 is the product of more than a decade of collaborative research', 'and to date, more than 2200 studies using the EORTC QLQ-C30 have been', 'registered with the EORTC (Fayers et al, 2001 [EORTC Scoring Manual]). The', 'EORTC QLQ-BLM30 is a 30-item questionnaire for patients with muscle invasive', 'bladder cancer (T2, T3, T4a and T4b). The muscle-invasive bladder cancer module', 'contains additional items assessing urostomy problems, problems associated with the', 'use of a catheter, and body image.', 'A paper booklet containing all the patient-reported outcomes will be administered in', 'clinic at baseline and every cycle visit at Mayo Clinic, and each PRO will be scored', 'according to the published scoring algorithm. Scale score trajectories over time will', 'be examined using stream plots and mean plots with standard deviation error bars', 'overall. Changes from baseline will be statistically tested using paired t-tests, and', 'standardized response means (mean of the change from baseline scores at a given', 'cycle, divided by the standard deviation of the change scores) will be interpreted', ""(after applying Middel's (2002) adjustment) using Cohen's (1988) cut-offs: <0.20 ="", 'trivial; 0.20-<0.50 = small; 0.50-<0.80 = moderate; and >=/0.80 = large. Correlation', 'between outcomes will employ Pearson and/or Spearman correlations at individual', 'time points.', '16.323 Progression-Free Survival (PFS): PFS will be defined as the time from registration', 'to time of first documentation of progression (as defined in Section 11.b) or death', 'due to any cause. Patients last known to be alive and not to have progressed are', 'censored at the last day of contact (or at study completion - 12 months). PFS rate at', '1 year will be estimated using the method of Kaplan-Meier (1958).', '16.324 Recurrence-Free Survival (RFS): RSF will be defined as the time from documented', 'complete response to the first documentation of recurrence (as defined in Section', '11.c). Patients last known to be alive and not to have recurred are censored at the last', 'day of contact (or at study completion - 12 months). RFS rate at 1 year will be', 'estimated using the method of Kaplan-Meier (1958),', '16.33', 'Exploratory & Correlative Endpoints: See section 2.3', 'Protocol Version Date: 21JUN2018']"
67,page_68,"['MC1752', '68', '16.34', 'Translational analyses: Given the small sample size, all translational analyses are', 'considered exploratory and no adjustment for multiplicity will be employed. One-sided', 'p-values <0.10 are considered statistically significant throughout. Results will be used to', 'design subsequent confirmatory studies (likely as translational components within the', 'subsequent phase III study should this phase II study support the use of this combination', 'in a phase III study).', 'We will explore the relationship of PD-L1 (SP263 and SP142 ), CD8+ by IHC and tumor', 'mutational burden ( Foundation Medicine Panel) and clinical response in order to', 'identify if these markers may be predictive of response. Association of Bim', 'Expression will be evaluated at using the baseline tissue specimen and explored in', 'relation to 6 months post-registration response and subsequently in relation to other', 'clinical outcomes such as tumor response and adverse event incidence using two-way', ""tables and analyzed using Fisher's exact tests. Expression of immune signatures"", 'by', 'RNA-sequencing (RNA-seq) expression (using the baseline tissue specimen) will be', 'evaluated at baseline and explored in relation to clinical outcomes such as progression-', 'free survival, tumor response, and adverse event incidence using two-way tables and', ""box plots and analyzed using Fisher's exact tests or logistic regression methods, as"", 'appropriate.', '16.4', 'Data & Safety Monitoring', '16.41', 'The principal investigator(s) and the study statistician will review the study at', 'least twice a year to identify accrual, adverse event, and any endpoint problems', 'that might be developing. The Mayo Clinic Cancer Center (MCCC) Data Safety', 'Monitoring Board (DSMB) is responsible for reviewing accrual and safety data', 'for this trial at least twice a year, based on reports provided by the MCCC', 'Statistical Office.', '16.42', 'Adverse Event Stopping Rule: The stopping rule specified below is based on the', 'knowledge available at study development. We note that the Adverse Event', 'Stopping Rule may be adjusted in the event of either (1) the study re-opening to', 'accrual or (2) at any time during the conduct of the trial and in consideration of', 'newly acquired information regarding the adverse event profile of the', 'treatment(s) under investigation. The study team may choose to suspend accrual', 'because of unexpected adverse event profiles that have not crossed the', 'specified rule below.', 'Accrual will be temporarily suspended to this study if at any time we observe events', 'considered at least possibly related to study treatment (ie, an adverse event with attribute', 'specified as ""possible"", ""probable"", or ""definite"") that satisfy the following:', 'if 4 or more patients in the first 10 treated patients (or 40% after 20 patients', 'have been accrued) experience a Grade 3 or higher non-hematologic adverse', 'event.', 'Protocol Version Date: 21JUN2018']"
68,page_69,"['MC1752', '69', 'We note that we will review Grade 4 and 5 adverse events deemed ""unrelated"" or', '""unlikely to be related"", to verify their attribution and to monitor the emergence of a', 'previously unrecognized treatment-related adverse event.', '16.5', 'Results Reporting on ClinicalTrials.gov: At study activation, this study will have been', 'registered within the ""ClincialTrails.gov"" website. The Primary and Secondary', 'Endpoints (i.e., ""Outcome Measures"") along with other required information for this', 'study will be reported on ClinicalTrials.gov. For purposes of timing of the Results', 'Reporting, the initial estimated completion date for the Primary Endpoint of this study is', '26 months after the study opens to accrual. The definition of ""Primary Endpoint', 'Completion Date"" (PECD) for this study is at the time the last patient registered has', 'completed the 6 months post-registration clinical follow-up.', '16.6', 'Inclusion of Women and Minorities', '16.61', 'This study will be available to all eligible patients, regardless of race, gender, or', 'ethnic origin.', '16.62', 'There is no information currently available regarding differential effects of this', 'treatment regimen in subsets defined by race, gender, or ethnicity, and there is', 'no reason to expect such differences to exist. Therefore, although the planned', 'analysis will, as always, look for differences in treatment effect based on racial', 'and gender groupings, the sample size is not increased in order to provide', 'additional power for subset analyses.', '16.63 Based on prior MCCC studies involving similar disease sites, we expect about', '5% of patients will be classified as minorities by race and 25% of patients will be', 'women. Expected sizes of racial by gender subsets are shown in the following', 'table:', 'Accrual Targets', 'Sex/Gender', 'Ethnic Category', 'Females', 'Males', 'Total', 'Hispanic or Latino', '1', '2', '3', 'Not Hispanic or Latino', '6', '21', '27', 'Ethnic Category: Total of all subjects', '7', '23', '30', 'American Indian or Alaskan Native', '0', '1', '1', 'Asian', '0', '0', '0', 'Black or African American', '0', '0', '0', 'Native Hawaiian or other Pacific Islander', '0', '0', '0', 'Protocol Version Date: 21JUN2018']"
69,page_70,"['MC1752', '70', 'Accrual Targets', 'Sex/Gender', 'Ethnic Category', 'Females', 'Males', 'Total', 'White', '7', '22', '29', 'Racial Category: Total of all subjects', '7', '23', '30', 'Ethnic', 'Hispanic or Latino - a person of Cuban, Mexican, Puerto Rico, South or Central', 'Categories:', 'American, or other Spanish culture or origin, regardless of race. The term ""Spanish', 'origin"" can also be used in addition to ""Hispanic or Latino.""', 'Not Hispanic or Latino', 'Racial', 'American Indian or Alaskan Native - a person having origins in any of the original', 'Categories:', 'peoples of North, Central, or South America, and who maintains tribal affiliations or', 'community attachment.', 'Asian - a person having origins in any of the original peoples of the Far East,', 'Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China,', 'India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and', 'Vietnam. (Note: Individuals from the Philippine Islands have been recorded as Pacific', 'Islanders in previous data collection strategies.)', 'Black or African American - a person having origins in any of the black racial', 'groups of Africa. Terms such as ""Haitian"" or ""Negro"" can be used in addition to', '""Black or African American.""', 'Native Hawaiian or other Pacific Islander - a person having origins in any of', 'the', 'original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.', 'White - a person having origins in any of the original peoples of Europe, the Middle', 'East, or North Africa.', '17.0', 'Pathology Considerations/Tissue Biospecimens', '17.1', 'Summary Table of Research Tissue Specimens to be Collected for this Protocol', 'Block,', 'Specimen', 'Slides, Core,', 'Process', 'Tempera', 'Research Study', 'Purpose', 'Mandat', 'Type of', 'etc. (# of', 'at site?', 'Conditi', '(Section for more', '(check all', 'ory or', 'Tissue to', 'each to', 'Archived', '(Yes or', 'for Stor', 'information)', 'that apply)', 'Optional', 'Collect', 'submit)', 'tissue', 'No)', '/Shipp', 'Correlative', 'Formalin', '5 charged', 'Correlative studies for', 'studies for', 'unstained', 'mRNA expression and', 'Fixed', 'mRNA', 'slides 5', 'whole genome analysis', 'Optional', 'Paraffin', 'X', 'No', 'Ambie', 'expression and', 'microns', 'Correlative Application', 'Embedded', 'MC1752-C1', 'whole genome', 'thick', 'analysis', 'sections', 'Protocol Version Date: 21JUN2018']"
70,page_71,"['MC1752', '71', '17.2', 'Diagnostic Slides from Original and /or Recurrent Tissue', 'Archived tissue may be collected per table 17.1 through next generation sequencing for', 'mRNA expression and whole genome analysis', 'Block retrieval and cutting will be determined at a later date.', '17.3', 'Correlative Tissue Collection', '17.31 Tissue Kits will not be provided for this protocol.', '17.32', 'Paraffin Embedded Tissue', '17.321', 'Archived tissue may be collected per table 17.1 through next', 'generation sequencing for mRNA expression and whole genome', 'analysis', '17.322', 'Block retrieval and cutting will be determined at a later date.', 'Shipping, accessioning, and processing information will be determined', 'at a later date. A modification will be submitted when information is', 'available.', '17.4', 'Background and Methodology', '17.41', 'See section 1.5 for correlative background information.', '17.42', 'Archived tissue may be collected per table 17.1 through next generation', 'sequencing for mRNA expression and whole genome analysis.', 'Protocol Version Date: 21JUN2018']"
71,page_72,"['MC1752', '72', '18.0', 'Records and Data Collection Procedures', '18.1', 'Data submission instructions', 'Data submission instructions for this study can be found in the Data Submission', 'Schedule.', '18.2', 'Survival Follow-up', 'Not applicable. Patients will be followed until EOS visit (12 months) only.', '18.3', 'CRF completion', 'This study will use Medidata Rave for remote data capture (rdc) of all study data. Data', 'collection for this study will be done exclusively through the Medidata Rave clinical data', 'management system. Access to the trial in Rave is granted through the iMedidata', 'application to all persons with the appropriate roles assigned in Regulatory Support', 'System (RSS). To access Rave via iMedidata, the site user must have an active account', 'and the appropriate Rave role (Rave CRA, Read-Only, Site Investigator) on either the', 'organization roster at the enrolling site.', '18.4', 'Site responsibilities', ""Each site will be responsible for insuring that all materials contain the patient's initials,"", ""MCCC registration number, and MCCC protocol number. Patient's name must be"", 'removed.', '18.5', 'Supporting documentation', 'This study requires supporting documentation for diagnosis prior to study entry as well as', 'for evidence of response to study therapy and progression after study therapy. 18.6', 'Labeling of materials', ""Each site will be responsible for insuring that all materials contain the patient's initials,"", ""MCCC registration number, and MCCC protocol number. Patient's name must be"", 'removed.', '18.7', 'Overdue lists', 'A list of overdue forms and outstanding queries will be available in Rave through the', 'Rave Task Summary. In addition to this, the Overdue Materials report is available on the', 'Cancer Center Systems homepage.', '19.0', 'Budget Considerations', '19.1', 'Tests to be research funded: Avelumab Study drug, Avelumab study drug administration,', 'ECG, urogram at EOS visit (12 month after registration), obtaining and processing of', 'archived research tissue specimens.', 'Protocol Version Date: 21JUN2018']"
72,page_73,"['MC1752', '73', '20.0', 'References', '1.', 'Mak RH, Hunt D, Shipley WU et al. Long-term outcomes in patients with muscle-invasive', 'bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of', 'Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol', '2014; 32: 3801-3809.', '2.', 'Gogna NK, Matthews JH, Turner SL et al. Efficacy and tolerability of concurrent weekly low', 'dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma:', 'a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother', 'Oncol 2006; 81: 9-17.', '3.', 'Hagan MP, Winter KA, Kaufman DS et al. RTOG 97-06: Initial report of a Phase I-II trial of', 'selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin,', 'and adjuvant MCV combination chemotherapy. International Journal of Radiation', 'Oncology*Biology*Physics 2003; 57: 665-672.', '4.', 'James ND, Hussain SA, Hall E et al. Radiotherapy with or without Chemotherapy in Muscle-', 'Invasive Bladder Cancer. New England Journal of Medicine 2012; 366: 1477-1488.', '5.', 'Kaufman DS, Winter KA, Shipley W et al. Muscle-invading bladder cancer, RTOG Protocol 99-', '06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated', 'irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine', 'chemotherapy. J Clin Oncol 2005; 23.', '6.', 'Kaufman DS, Winter KA, Shipley WU et al. The initial results in muscle-invading bladder cancer', 'of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin', 'and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial', 'response. Oncologist 2000; 5: 471-476.', '7.', 'Mitin T, Hunt D, Shipley WU et al. Transurethral surgery and twice-daily radiation plus', 'paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant', 'chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre', 'phase 2 trial. The lancet oncology 2013; 14: 863-872.', '8.', 'Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in', 'patients with invasive bladder cancer treated with selective bladder preservation by combined radiation', 'therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol', '1998; 16: 3576-3583.', '9.', 'Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective', 'organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II', 'trial 8802. Journal of Clinical Oncology 1996; 14: 119-126.', '10.', 'Tester W, Porter A, Asbell S et al. Combined modality program with possible organ preservation', 'for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25:', '783-790.', '11.', 'Giacalone NJ, Shipley WU, Clayman RH et al. Long-term Outcomes After Bladder-preserving', 'Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the', 'Massachusetts General Hospital Experience. Eur Urol 2017.', '12.', 'Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the', 'immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.', '13.', 'Sistigu A, Yamazaki T, Vacchelli E et al. Cancer cell-autonomous contribution of type I', 'interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20: 1301-1309.', '14.', 'Wu CT, Chen WC, Chang YH et al. The role of PD-L1 in the radiation response and clinical', 'outcome for bladder cancer. Sci Rep 2016; 6: 19740.', '15.', 'Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced', 'and metastatic urothelial carcinoma who have progressed following treatment with platinum-based', 'chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909-1920.', 'Protocol Version Date: 21JUN2018']"
73,page_74,"['MC1752', '74', '16.', 'Bellmunt J, de Wit R, Vaughn DJ et al. AvelumabAvelumabAvelumab as Second-Line Therapy', 'for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376: 1015-1026.', '17.', 'Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for', 'curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008; 22: 1064-1070;', 'discussion 1075, 1080-1061, 1084.', '18.', 'Apolo AI, J. R. et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic', 'urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity,', 'and PD-L1 expression. J Clin Oncol 34, 2016 (suppl; abstr 4514).', '19.', 'Chang SS, Bochner BH, Chou R et al. Treatment of Non-Metastatic Muscle-Invasive Bladder', 'Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol; 198: 552-559, 2017.', 'Protocol Version Date: 21JUN2018']"
74,page_75,"['MC1752', '75', 'Appendix I', 'ECOG Performance Status', 'ECOG PERFORMANCE STATUS*', 'Grade', 'ECOG', '0', 'Fully active, able to carry on all pre-disease performance without restriction', '1', 'Restricted in physically strenuous activity but ambulatory and able to carry out', 'work of a light or sedentary nature, e.g., light house work, office work', '2', 'Ambulatory and capable of all selfcare but unable to carry out any work', 'activities. Up and about more than 50% of waking hours', '3', 'Capable of only limited selfcare, confined to bed or chair more than 50% of', 'waking hours.', '4', 'Completely disabled. Cannot carry on any selfcare. Totally confined to bed or', 'chair.', '5', 'Dead', '*As published in Am. J. Clin. Oncol.:', 'Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.:', 'Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-', '655, 1982.', 'The ECOG Performance Status is in the public domain therefore available for public use. To duplicate the', 'scale, please cite the reference above and credit the Eastern Cooperative Oncology Group, Robert Comis', 'M.D., Group Chair.', 'From http://www.ecog.org/general/perf stat.html', 'Protocol Version Date: 21JUN2018']"
75,page_76,"['ENGLISH', 'Appendix II', 'EORTC QLQ-C30', 'EORTC QLQ-C30 (version 3)', 'We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that', 'best applies to you. There are no ""right"" or ""wrong"" answers. The information that you provide will remain strictly confidential.', 'Please fillin yourinitials:', 'Your birthdate (Day, Month, Year):', ""Today's date (Day, Month, Year):"", '31', 'Not at', 'A', 'Quite', 'Very', 'All', 'Little', 'a Bit', 'Much', '1. Do you have any trouble doing strenuous activities,', 'like carrying a heavy shopping bag or a suitcase?', '1', '2', '3', '4', '2. Do you have any trouble taking a longwalk?', '1', '2', '3', '4', '3.', 'Do you have any trouble taking a short walk outside of the house?', '1', '2', '3', '4', '4. Do you need to stay in bed or a chair during the day?', '1', '2', '3', '4', '5.', 'Do you need help with eating, dressing, washing', 'yourself or using the toilet?', '1', '2', '3', '4', 'Not at', 'During the past week:', 'A', 'Quite', 'Very', 'All', 'Little', 'a Bit', 'Much', '6. Were you limited in doing either your work or other daily activities?', '1', '2', '3', '4', '7.', 'Were you limited in pursuing your hobbies or other', 'leisure time activities?', '1', '2', '3', '4', '8. Were you short of breath?', '1', '2', '3', '4', '9. Have you had pain?', '1', '2', '3', '4', '10. Did you need to rest?', '1', '2', '3', '4', '11. Have you had trouble sleeping?', '1', '2', '3', '4', '12. Have you felt weak?', '1', '2', '3', '4', '13. Have you lacked appetite?', '1', '2', '3', '4', '14. Have you felt nauseated?', '1', '2', '3', '4', '15. Have you vomited?', '1', '2', '3', '4', '16. Have you been constipated?', '1', '2', '3', '4', 'Please go on to the next page', 'Protocol Version Date: 21JUN2018']"
76,page_77,"['ENGLISH', 'During the past week:', 'Not at', 'A', 'Quite', 'Very', 'All', 'Little', 'a Bit', 'Much', '17. Have you had diarrhea?', '1', '2', '3', '4', '18. Were you tired?', '1', '2', '3', '4', '19. Did pain interfere with your daily activities?', '1', '2', '3', '4', '20. Have you had difficulty in concentrating on things,', 'like reading a newspaper or watching television?', '1', '2', '3', '4', '21. Did you feel tense?', '1', '2', '3', '4', '22. Did you worry?', '1', '2', '3', '4', '23. Did you feel irritable?', '1', '2', '3', '4', '24. Did you feel depressed?', '1', '2', '3', '4', '25. Have you had difficulty remembering things?', '1', '2', '3', '4', '26. Has your physical condition or medical treatment', 'interfered with your family life?', '1', '2', '3', '4', '27. Has your physical condition or medical treatment', 'interfered with your social activities?', '1', '2', '3', '4', '28. Has your physical condition or medical treatment', '1', '2', '3', '4', 'caused you financial difficulties?', 'For the following questions please circle the number between 1 and 7 that best applies to', 'you', '29. How would you rate your overall health during the pastweek?', '1', '2', '3', '4', '5', '6', '7', 'Very poor', 'Excellent', '30. How would you rate your overall quality of life during the past week?', '1', '2', '3', '4', '5', '6', '7', 'Very poor', 'Excellent', 'C Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0', 'Protocol Version Date: 21JUN2018']"
77,page_78,"['ENGLISH', 'Appendix III EORTC QLQ-BLM30', 'EORTC OLO - BLM30', 'Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you', 'have experienced these symptoms or problems during the past week. Please answer by circling the number that best', 'applies to you.', 'PLEASE ANSWER QUESTIONS 31 - 37 ONLY IF YOU DO NOT HAVE A UROSTOMY', 'During the past week:', 'Not', 'A', 'Quite', 'Very', 'at all', 'little', 'a bit', 'much', '31.', 'Have you had to urinate frequently during the day?', '1', '2', '3', '4', '32.', 'Have you had to urinate frequently at night?', '1', '2', '3', '4', '33.', 'When you felt the urge to pass urine,', 'did you have to hurry to get to the toilet?', '1', '2', '3', '4', '34.', 'Was it difficult for you to get enough sleep, because', '1', '2', '3', '4', 'you needed to get up frequently at night to urinate?', '35.', 'Have you had difficulty going out of the house,', 'because you needed to be close to a toilet?', '1', '2', '3', '4', '36.', 'Have you had any unintentional release (leakage) of urine?', '1', '2', '3', '4', '37.', 'Have you had pain or a burning feeling when urinating?', '1', '2', '3', '4', 'PLEASE ANSWER QUESTIONS 38 - 43 ONLY IF YOU HAVE A UROSTOMY', 'During the past week:', 'Not', 'A', 'Quite', 'Very', 'at all', 'little', 'a bit', 'much', '38.', 'Has urine leaked from your urostomy bag?', '1', '2', '3', '4', '39.', 'Did you have problems with caring for your urostomy?', '1', '2', '3', '4', '40.', 'Was your skin around the urostomy irritated?', '1', '2', '3', '4', '41.', 'Have you felt embarrassed because of your urostomy?', '1', '2', '3', '4', '42.', 'Have you been dependent on others for', '1', '2', '3', '4', 'caring for your urostomy?', '43.', 'Did you frequently have to change the urostomy bag?', '1', '2', '3', '4', 'PLEASE ANSWER QUESTION 44 ONLY IF YOU HAVE USED A CATHETER DURING THE PAST WEEK', '44.', 'Have you had problems with self-catheterization?', '(inserting a tube in the bladder to pass urine)', '1', '2', '3', '4', 'Please go on to the next page', 'Protocol Version Date: 21JUN2018']"
78,page_79,"['ENGLISH', 'During the past week:', 'Not', 'A', 'Quite', 'Very', 'at all', 'little', 'a bit', 'much', '45.', 'Were you worried about your health in the future?', '1', '2', '3', '4', '46.', 'Did you worry about the results of examinations and tests?', '1', '2', '3', '4', '47.', 'Did you worry about possible future treatments?', '1', '2', '3', '4', '48.', 'Have you had a bloated feeling in your abdomen?', '1', '2', '3', '4', '49.', 'Have you had flatulence or gas?', '1', '2', '3', '4', '50.', 'Have you felt physically less attractive as', '1', '2', '3', '4', 'a result of your illness or treatment?', '51.', 'Have you been dissatisfied with your body?', '1', '2', '3', '4', '52.', 'Have you felt less feminine/masculine as', '1', '2', '3', '4', 'a result of your illness or treatment?', 'During the past 4 weeks:', 'Not', 'A', 'Quite', 'Very', 'at all', 'little', 'a bit', 'much', '53.', 'To what extent were you interested in sex?', '1', '2', '3', '4', '54.', 'To what extent were you sexually active', '(with or without sexual intercourse)?', '1', '2', '3', '4', '55.', 'For men only: Did you have difficulty gaining', '1', '2', 'or maintaining an erection?', '3', '4', '56.', 'For men only: Did you have ejaculation problems', '1', '2', '3', '4', '(e.g. dry ejaculation)?', 'Please answer the following 4 questions only if you', 'Not', 'A', 'Quite', 'Very', 'have been sexually active during the past 4 weeks:', 'at all', 'little', 'a bit', 'much', '57.', 'Have you felt uncomfortable about being', '1', '2', '3', '4', 'sexually intimate?', '58.', 'Have you worried that you may contaminate', 'your partner during sexual contact with the', 'bladder treatment you have been', '1', '2', '3', '4', 'receiving?', '59.', 'To what extent was sex enjoyable for you?', '1', '2', '3', '4', 'Protocol Version Date: 21JUN2018']"
79,page_80,"['ENGLISH', '60.', 'For Women only: did you have a dry vagina', '1', '2', '3', '4', 'or other problems during intercourse?', 'C', 'Copyright 1994 EORTC Quality of Life Study Group, version 1.0 All rights reserved.', 'Protocol Version Date: 21JUN2018']"
80,page_81,"['ENGLISH', 'Appendix IV Patient Information Sheet', 'Patient Information Sheet', 'Screening & Active Monitoring Phase', 'Page 1 of 5', 'You have been given a booklet to complete for this study. The booklet contains some', 'questions about your health as a patient receiving treatment. Your answers will help us to', 'better understand how the treatment you are receiving is affecting the way you feel.', 'This booklet contains:', 'The EORTC QLQ-C30: complete during your scheduled clinic visit (Screening,', 'end of avelumab treatment, end of study)', 'The EORTC QLQ-BLM30: complete during your scheduled clinic visit', '(Screening, end of avelumab treatment, end of study)', 'Thank you for taking the time to help us.', 'Protocol Version Date: 21JUN2018']"
